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Blood vessels are among the first organs to develop during
embryogenesis and are essential for organogenesis and nutrition
of the embryo. Although formation of blood vessels most actively
occurs during embryonic development, tissue vascularization pro-
ceeds after birth in the retina, in the heart, and, cyclically, in the
reproductive organs. In addition, abnormal vessel growth impor-
tantly contributes to the pathogenesis of several disorders with
high morbidity and mortalitiy. Excessive vessel growth has been
implicated in the pathogenesis of retinopathies, cancer and in-
flammation. In contrast, insufficient vessel growth may lead to
tissue ischemia and failure. Although formation of new blood
vessels has typically been associated with endothelial cells, the
periendothelial mural pericytes (smaller vessels) or smooth mus-
cle cells (larger vessels) are equally important for normal and
pathological vessel formation. Indeed, a developing network of
endothelial tubes that is not surrounded by mural cells is fragile
and prone to rupture, remains susceptible to hypoxic regulation,
fails to become remodeled, is unable to sustain proper circulation,
and cannot adapt to changes in physiological demands of blood
supply. Notably, vascular growth does not always involve forma-
tion of new capillaries, but may depend on remodeling of pre-
existing arteriolized vessels, such as during collateral growth in the
myocardium. The importance of periendothelial cells is further
deduced from the pathological loss of smooth muscle cells in
atherosclerotic vessels (leading to media necrosis), or from the
“pericyte drop out” in diabetic retinal vessels, which renders them
prone to aneurysmal rupture. Conversely, accumulation of
smooth muscle cells contributes to atherosclerotic plaque growth
and arterial stenosis. Recent studies have highlighted the impor-
tance of endothelial 7 periendothelial cell crosstalk during
normal and pathological blood vessel formation. Accordingly,
integrated research into the molecular mechanisms that regulate
the development and function of both endothelial and pericyte/
smooth muscle cells has become a major focus in vascular biology.
A number of candidate molecules (growth factors, matrix compo-
nent, adhesion molecules, and proteinases) have been identified
that stimulate or inhibit these processes. Recently, remarkable
progress in their molecular analysis has been achieved through
targeted manipulation of the mouse genome. Their role will be
discussed in this review.
ENDOTHELIAL CELLS
Assembly of endothelial cells in embryonic blood vessels
Distinct cellular processes mediate blood vessel formation
during embryogenesis [1–6]. Initially, mesodermal cells differen-
tiate in situ into early hemangioblasts and form cellular aggregates
(blood islands), in which the inner cell population develops into
hematopoietic precursors and the outer cell population gives rise
to the primitive endothelial cells. In vitro findings suggest that
basic fibroblast growth factor (bFGF or FGF2) may participate in
angioblast differentiation via induction of a cellular receptor for
vascular endothelial growth factor (VEGF-A) [7].
The second stage involves “vasculogenesis”, during which en-
dothelial cells fuse and form a primordial vascular network. The
larger vessels of the embryo and the primary vascular plexus in the
lung, the pancreas, the spleen, the heart and the yolk sac arise by
this process [1]. Lumen formation of the primitive capillaries, an
essential aspect of vasculogenesis, may result from endothelial
vacuolization (intracellular lumen formation), or from a continu-
ation of the pre-existing lumen through the joining of distal
endothelial cells (intercellular lumen formation). Gene inactiva-
tion studies in mice indicate that these processes are controlled by
VEGF-A [8, 9], fibronectin [10], the a5 integrin receptor [11],
VE-cadherin [12], transforming growth factor (TGF)-b1 [13], and
possibly FGF2 (see below). Whereas the VEGF-A receptor FLK1
may be involved in positive regulation [14], another VEGF-A
receptor FLT1 may antagonistically inhibit this process [15]. In
addition, immunoneutralization studies in the avian embryo indi-
cate that the avb3 integrin is involved in endothelial spreading and
in the formation of endothelial protrusions, required for lumen
formation and vessel patterning [16].
During the third phase, a primitive vascular plexus develops
into a complex organized and interconnecting network. One
mechanism involves intussusceptive microvascular growth,
whereby a pre-existing vessel is split into two daughter vessels by
the formation of transcapillary pillars and by invagination by
surrounding pericytes and extracellular matrix [17–19]. This pro-
cess, whereby sinusoidal capillaries generate loops that remain
constantly perfused, seems to be of special importance in the lung,
but is probably more widespread than originally considered. It is
also the predominant mechanism for VEGF-induced vascular
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growth in the chicken allantoic membrane [17, 20]. Although its
molecular mechanisms remain largely unknown, VEGF-A [8, 9],
the angiopoietins (ANG) and the TIE receptors [21–25], and
several extracellular matrix components [10] may be implicated. A
second mechanism of network expansion involves sprouting of
new blood vessels from a preexisting blood vessel (“angiogene-
sis”), such as occurs in the brain, the kidney and the intersomitic
vessels. It is controversial whether endothelial cells migrate first
and are followed by sprouting pericytes, or rather, whether
pericytes pave the way by hollowing out the extracellular matrix,
thereby allowing the sprouting endothelial cells to fill in the
pericyte tube [26]. Whereas the latter mechanism may occur
during adult neovascularization, the former mechanism appears
to be more prevalent during embryonic vascular development. In
order for endothelial (or pericyte) cells to emigrate from their
pre-existing site, they first need to proteolytically degrade the
surrounding basement membrane (plasminogen activators and
matrix metalloproteinases [27]), to loosen their interendothelial
cell contacts (VE-cadherin [12]), and to relieve the periendothe-
lial cell support (ANG2 [24]). The endothelial cells need to
proliferate, to change their shape, to protrude extensions, and to
migrate towards the angiogenic stimulus (VEGF-A [8, 9]; the avb3
integrin [16]) (initiation step). Subsequently, the endothelial cells
are assembled in cords which form a lumen (VEGF-A [8, 9]; the
avb3 integrin [16]), and fuse with other vessels (fibronectin [10];
VCAM-1 [28, 29]; a4 integrin [30]). As the endothelial tubes
mature, they become surrounded by periendothelial mural cells
(ANG1 and TIE2 [23]; tissue factor [31]; PDGF-B [32, 33];
TGF-b1 [13]) (maintenance and termination steps). Somewhat
surprisingly, certain extracellular matrix components (vitronectin
[34]) and proteinases [27] did not affect this process. This suggests
that several mechanisms of embryonic vascular development are
redundant or that they are compensated. It is conceivable that
angiogenesis inhibitors are involved in the termination of sprout-
ing, but insights into their biological role await future study. A
third mechanism involves the intercalated growth of blood vessels
(“non-sprouting angiogenesis”) whereby pre-existing capillaries
merge, or additional endothelial cells fuse into existing vessels to
increase their diameter and length. This process is important for
vessel growth in the heart and during the healing of endothelial
wounds [17, 20], but its molecular mechanisms remain enigmatic.
Hypoxia and metabolic stress are somehow important for these
early steps of embryonic vascularization, as evidenced by the
vascular defects in embryos lacking the arylhydrocarbon-receptor
nuclear translocator (ARNT) [35, 36], the hypoxia-inducible
factor (HIF)-1a (unpublished observations), or the von Hippel-
Lindau gene product [37]. Although distinct tissues have been
proposed to be vascularized by either vasculogenic or angiogenic
processes, more recent evidence challenges such a dogmatic
classification, as primary angioblasts with resultant vasculogenesis
have also been observed in the neural tube, the kidney and the
somites [1, 38].
After the onset of circulation (such as during the organogenetic
period; fourth phase), this emerging vascular plexus becomes
remodeled and pruned into a tree of veins, capillaries and arteries,
the expansion of which is matching the metabolic demands of the
growing embryo. It involves fusion and regression of blood vessels,
changes in lumen diameter and vessel wall thickness, and the
deposition of specialized extracellular matrix components (elastin,
fibrillins), which provide the vessel with novel properties (vis-
coelasticity). Metabolic, hydrodynamic, hypoxic or rheologic fac-
tors, and the interaction between endothelial and mural cells may
determine these processes. Vessel regression may result from
endothelial cell emigration, transdifferentiation or death [1]. Both
the loss of endothelial survival signals [39, 40], and the production
of death factors could mediate the latter process. Developmen-
tally programmed vessel regression has been studied in greater
detail in the hyaloid capillary network in the eye during the first
three weeks after birth [41, 42]. A macrophage-related cell, called
the hyalocyte, induces apoptosis in some of the endothelial cells
by secreting death factors such as tumor necrosis factor (TNF)-a,
nitric oxide and reactive oxygen species (initiating apoptosis).
Shedding of dead cells results in obstruction of the lumen [43],
inducing synchronous endothelial cell death (secondary apopto-
sis) due to deprivation of survival factors (VEGF, FGF2, or
platelet-derived growth factor; PDGF), or altered shear stress-
dependent gene expression (PDGF, FGF2). Changes in perien-
dothelial cell support also play a role in vessel regression, as
PDGF-induced emigration of pericytes induces endothelial cell
death in the retina (Benjamin and Keshet, personal communica-
tion). Interestingly, ANG2 has been associated with vessel regres-
sion, but presumably only at low VEGF levels [24, 44]. Integrin
avb3 also provides an essential survival function for angiogenic
but not for quiescent endothelial cells [45].
Another characteristic of this phase of blood vessel develop-
ment is that endothelial cells acquire particular heterogeneity due
to specialized differentiation, which appears to be dependent on
interactions with local parenchymal cells [1, 46]. For example,
astrocytes appear responsible for the induction of the blood-
brain-barrier, whereas choroidal epithelial cells induce the forma-
tion of fenestrated capillaries. Although the molecular mecha-
nisms of such organ-specific differentiation remain largely
unknown, the different VEGF-A splice forms have been sug-
gested to be involved in the formation and the maintenance of a
fenestrated endothelium [1, 46].
Assembly of endothelial cells in adult blood vessels
Although most organs become vascularized during embryogen-
esis, vascular development after birth proceeds in the heart [47,
48] and in the retina [49]. In addition, new blood vessels during
adulthood are formed in the reproductive organs and during
pathological conditions of inflammation, tumorigenesis, tissue
ischemia or diabetes [50–53]. Several of the mechanisms mediat-
ing postnatal blood vessel formation largely resemble those during
embryogenesis. As in the embryo, VEGF-A mediates (neo)vas-
cularization in the neonatal and the ischemic heart [47, 48, 54], in
the retina [49, 54, 55], in the ovary and the uterus, and in tumors
[50, 55, 56]. Other molecules also play a role in adult blood vessel
formation, for example, FGF2 and TGF-b1 in the neonatal and
the ischemic heart [47, 48, 57–59]. Distinct mechanisms may
control adult (neo)vascularization, altough some of these ‘appar-
ent’ differences in the mechanisms between embryonic and adult
vessel formation may rather reflect our incomplete understanding
of these processes. For example, adult blood vessel formation may
be affected by insulin-like growth factor (IGF)-1 in the heart [57,
59], by nitric oxide in ischemic limbs [60], by the angiopoietins in
the ovaries [24], and by erythropoietin in the uterus. Inhibitors of
vessel formation have been much less characterized in the embryo
than in the adult [61–63]. Proteinases (matrix metalloproteinases
and plasminogen activators) may play a more significant role
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during pathological neovascularization than during embryonic
vascular development [64], possibly because of differences in the
composition of the extracellular matrix and the expression pattern
of proteinases. Another difference is that vasculogenesis per se
(such as the in situ differentiation of angioblasts) was (at least
until recently) believed only to occur in the embryo. However,
endothelial stem cell progenitors have been recently identified in
the peripheral blood, which were shown to differentiate in situ to
endothelial cells in ischemic tissues and in tumors [65].
Another difference is that adult endothelial cells are quiescent
(in contrast to the actively growing embryonic endothelial cells),
and need to be stimulated to grow. One particular cell type that
may trigger adult neovascularization during heart ischemia, can-
cer and inflammation is the monocyte/macrophage [66, 67]. These
cells can influence blood vessel formation in many ways. They can
degrade the extracellular matrix via production of proteinases [68,
69], but can also promote the synthesis of matrix components
through release of TGF-b1. In addition, they secrete several
monokines (FGF2, PDGF) that attract or induce the growth of
fibroblasts and smooth muscle cells, which are able to produce
matrix components [66]. In addition, they produce a myriad of
angiogenic factors (VEGF-A, FGF2, TGF-b1, interleukin-8,
PDGF, IGF-1) as well as of angiogenesis inhibitors (throm-
bospondin, interferons). They also produce proteinases that can
activate growth factors (TGF-b1 [70]), or liberate them from the
extracellular matrix (effect of plasmin and heparanases on FGF2
[71], VEGF-A [72] or IGF-1 [73]). In addition, their proteinases
generate angiogenisis inhibitors, such as angiostatin, which is
cleaved from plasminogen by metalloelastase [74] or plasmin [75].
Thus, evidence is emerging that distinct mechanisms may govern
adult blood vessel formation.
Assembly of endothelial cells in lymphatic vessels
In contrast to the vast literature on blood vessel development,
few studies have characterized the development of the lymphatic
vasculature [76, 77]. Lymphatic capillaries are present in most
tissues except in the central nervous system and the intralobular
portion of the liver. They form a widely interconnected system of
thin-walled channels, varying greatly in luminal diameter (from 10
to 50 mm). Their irregular wall consists only of endothelial cells
(without pericytes or adventitial cells), which are surrounded by
layers of fine collagenous and reticular fibrils. Adjacent endothe-
lial cells form end-to-end, overlapping and interdigitating junc-
tions without valves. The absence of junctional complexes and of
a continous basal lamina, and their thin permeable endothelium
with micropinocytotic vesicles render these lymphatics suited for
passive reabsorption of water, electrolytes, proteins, macromole-
cules, cell fragments and mobile inflammatory or tumor cells. The
lymphatic capillaries merge into collecting lymphatic vessels,
which conduct the lymph to and through regional lymph nodes.
The walls of these lymphatic collecting vessels consist of a thin
endothelial lining, a sheet of reticular fibrils, an incomplete layer
of smooth muscle cells, and an adventitial layer of connective
tissue. In addition, there are many valves, with the cusps project-
ing in the direction of the lymph flow. After filtration through the
nodes, the lymph is delivered to the venous system by either the
thoracic or the right lymphatic duct. Their wall contains the three
typical layers (tunica intima, media and adventitia), particularly
the tunica media, which contains bundles of smooth muscle cells
that are oriented longitudinally or circularly. In certain lymph
vessels (mesenteric, tracheobronchial and mediastinal), rhythmic
spontaneous contractions, which are under the control of neural,
humoral and endothelial-derived factors, modulate resistance to
lymph flow [78, 79].
Remarkably little is known about the development of the
lymphatic vasculature during embryogenesis. The study of the
lymphatic vasculature has been largely hampered by the lack of
specific markers, and only recently has VEGF receptor-3 or FLT4
been identified as a possible lymph-specific marker (see also
below) [80]. It has been proposed that the lymphatic structures
sprout from large central veins (anterior cardinal veins in the
neck, mesonephric veins, veins in the dorsomedial edge of the
Wolffian bodies) to form the primordial lymph sacs [81]. These
venous structures are FLT4 positive around 11.5 days of gestation
[80]. Subsequently, these sacs enlarge, coalesce, and form new
sprouts, which grow into the periphery of the embryo, whereas the
main lymphatic ducts form by union of duct primordia [82–84].
These vessels are also FLT4 positive beyond 14 days of gestation.
The molecular mechanisms governing lymphangiogenesis remain,
however, largely undefined, and only recently has a putative
lymphangiogenic factor (VEGF-C) been identified. The specific-
ity of these findings may be deduced from the fact that VEGF-A
isoforms did not affect lymphangiogenesis [20]. The relevance of
these markers for tumor-asssociated lymphangiogenesis remains
undefined. The following section reviews the role of those mole-
cules (and in paritcular of VEGF-A) that appear to be the key
players during vascular development, as primarily deduced from
the gene targeting studies.
The vascular endothelial growth factor (VEGF) family
VEGF-A: Structure and gene organization. Vascular endothelial
growth factor (VEGF-A), unlike other known angiogenic factors,
has a unique combination of properties: (i) it is produced by cells
in close vicinity to endothelial cells, suggesting paracrine regula-
tion of blood vessel formation [85, 86]; (ii) it is secreted and exerts
a direct and largely restricted effect on endothelial cells via
interaction with cellular receptors FLK1 (VEGF receptor-2) and
FLT1 (VEGF-receptor-1) [87]; (iii) it induces a pleiotropic re-
sponse allowing endothelial cells to proliferate, to migrate, to
assemble into tubes, and to survive, and is one of the most potent
permeability factors [55, 56, 88]; (iv) its expression is highly
regulated by hypoxia, providing a physiological feedback mecha-
nism to accomodate insufficient tissue oxygenation by promoting
blood vessel formation [54]; and (v) it is a potent growth factor
since its over- or under-expression significantly affects blood
vessel formation in vivo [8, 9, 89, 90].
VEGF-A is transcribed from a single gene that is alternatively
processed in various isoforms [91]. The shortest form (VEGF-
A121) is freely diffusible in the surrounding extracellular milieu,
whereas the longer isoforms (VEGF-A165, VEGF-A189 and
VEGF-A206) display an increasing binding to heparin-rich extra-
cellular matrix [55, 56, 88]. The mouse has only three isoforms
that lack one amino acid residue (VEGF-A120, VEGF-A164 and
VEGF-A188). VEGF-A165 can be liberated from the extracellular
matrix by the serine proteinase plasmin that cleaves it into a
mitogenic carboxy-terminal polypeptide (VEGF-A111-165), and an
amino-termimal VEGF-A110 fragment with reduced binding to
the VEGF receptors FLT1 and FLK1 [72]. Notably, VEGF-A110
and VEGF-A121 have reduced endothelial cell mitogenic potency
Carmeliet and Collen: Vascular development and disorders 1521
more than 100-fold than VEGF-A165, indicating that the carboxy-
terminal residues are critical for mitogenic potency. Since removal
of the carboxy-terminal domain (whether due to alternative
splicing of mRNA or to proteolysis) increases the solubility but
reduces the bioactivity of VEGF-A, it is possible that these
different VEGF-A isoforms provide a spatial gradient of pattern-
ing information during blood vessel formation, such as the longer
matrix-attached isoforms (close to the site of VEGF-A produc-
tion) provide a stronger mitogenic signals than the shorter, more
diffusible VEGF-A isoforms. Such a mechanism would attract
endothelial cells to ischemic or avascular sites. The various
isoforms exhibit a tissue-specific and temporal pattern of expres-
sion (for example VEGF-A188 is more abundant in the adult
mouse heart and lung, whereas VEGF-A164 is the primary form in
brain and kidney), but their differential (patho)physiologicial role
in vivo remains largely undetermined [92].
VEGF-A: Biological role. The pleiotropic actions of VEGF-A
render this molecule ideally suited to modulate blood vessel
formation. VEGF-A stimulates endothelial proliferation [56, 88]
and reduces endothelial death [40]. The survival function of
VEGF-A may be important as reduced levels have been associ-
ated with endothelial apoptosis, shedding into and obstructing the
lumen, resulting in vascular collapse with hemorrhaging and
vessel regression [39]. VEGF-A can stimulate endothelial migra-
tion via an effect on motility, proteolysis, cell-adhesion and
-junction, and permeability. It increases the release of matrix
metalloproteinases (MMPs) and plasminogen activators (PAs)
[69]. Proteolytically active MMP2 binds the avb3 integrin, thereby
linking matrix adhesion to regulation of proteinase activity [93]. In
addition, recent evidence suggests that urokinase-type plasmino-
gen activator (u-PA), its cellular receptor (u-PAR) and the
plasminogen activator inhibitor-1 (PAI-1) may control cell migra-
tion in a proteolysis-independent interaction with vitronectin and
its avb3 integrin receptor, although the precise mechanisms and
the consequences on cellular migration are still unclear. Indeed,
proteolytically inactive u-PA may promote migration by displacing
PAI-1 from vitronectin, allowing the latter to bind to the avb3
integrin [94]. It is possible that u-PAR, which colocalizes with
avb5 and possibly with other integrins on migrating cells [95], is
also involved in this interaction, as u-PA alters the conformation
of u-PAR, favoring interaction of the latter with vitronectin [96,
97]. It remains, however, unclear whether enhanced vitronectin-
adhesion promotes or retards cell migration, since migration
would result from a dynamic interaction between adhesion and
de-adhesion. VEGF-A also induces endothelial expression of the
avb3 integrin (and presumably also of the avb5 integrin), which
are receptors for vitronectin and/or fibronectin, fibrinogen and
osteopontin [98, 99]. VEGF-stimulated microvascular endothelial
cells produce increased amounts of osteopontin, which promotes
endothelial migration [100]. In addition, VEGF-A may coordinate
endothelial cell migration by increasing intercellular communica-
tion via induced connexin 43 expression [101].
An important property of VEGF-A is its ability to increase
vascular permeability, possibly via rapid formation of capillary
fenestrations [102], the assembly of vesiculo-vacuolar organelles,
or the opening of intercellular junctions or transcellular gaps
[103]. As a result, plasma coagulation factors and other plasma
proteins (fibronectin, vitronectin, fibrinogen) leak out in the
perivascular compartment. Since VEGF-A induces expression of
tissue factor (the cellular initiator of blood coagulation) [104], a
fibrin seal is formed which together with the other plasma proteins
provide a scaffold for migrating cells [100]. In addition, tissue
factor promotes smooth muscle migration directly [31, 105] and
indirectly through generation of thrombin [106]. Through a
feedback induction of VEGF-A release, tissue factor may further
increase leakage [107, 108]. VEGF-A also promotes expression of
VCAM-1 and ICAM-1 on endothelial cells, resulting in the
adhesion of leukocytes [109]. As the latter cells may influence
endothelial permeability [110], and release a myriad of angiogenic
growth factors [67], VEGF-A establishes a direct link between
inflammation, permeability and angiogenesis.
The role of VEGF-A may not be entirely restricted to endo-
thelial cells since VEGF receptors are also found on other cell
types. Indeed, VEGF-A may control vessel formation via recruit-
ment of macrophages [104, 111, 112], which produce a variety of
angiogenic factors. This process may be particularly relevant
during inflammation or myocardial angiogenesis [66]. In addition,
by stimulating pericyte recruitment or smooth muscle cell migra-
tion [113–115], VEGF-A may aid the maturation of the endothe-
lial tubes, which, once surrounded by pericytes, may become less
responsive to hypoxia regulation (Benjamin and Keshet, personal
communication). VEGF-A increases the number of muscular
vessels in the ischemic heart, presumably via stimulation of
endothelial release of PDGF [116]. It may also induce vasodila-
tion of arterioles via release of endothelial nitric oxide, contrib-
uting to the hyperemia in tissues undergoing neovascularization
[117, 118]. In contrast, VEGF-2 (or VEGF-C; another VEGF
homologue; see below) appears to inhibit PDGF-stimulated pro-
liferation of smooth muscle cells [119], suggesting distinct func-
tions for each of the VEGF family members.
Other cell types are responsive to VEGF-A. It affects differen-
tiation of osteoblasts and of haematopoietic cells, regulates the
production of insulin in pancreatic b-cells, and has an as yet
unidentified effect on melanoma cells [88, 120, 121]. It also
inhibits maturation of host antigen-presenting cells (dendritic
cells), suggesting that it may facilitate tumor growth by allowing
the tumor to avoid the induction of an immune response [122].
The biological role of VEGF-A appears to be contextual, that
is, its effect is determined by the presence of other signals such as
FGF2, TGF-b1, PDGF, ANGs, etc. [24, 44, 123]. Some of these
molecules amplify the role of VEGF-A [99, 124, 125], whereas
others such as angiostatin and, likely other (yet to be defined)
factors inhibit its action. Moreover, VEGF-induced permeability
of vessels is different in various tissues, suggesting an important
role of the microenvironment in the overall angiogenic effect of
VEGF-A [126]. In certain tissues such as the mammary gland
during gestation, VEGF-A is present but does not seem to
correlate with the vascularization response.
VEGF-A: Expression. The pattern of expression of the VEGF-
ligands and their receptors during embryogenesis suggests a role
for these molecules in vascular development. VEGF-A is pro-
duced by cells in close vicinity to the developing endothelial cells,
such as in the visceral endoderm cells in the yolk sac, or in the
ventricular zone of the developing brain [85]. The VEGF recep-
tors FLT1 and FLK1 (see below) have distinct but overlapping
temporo-spatial expression patterns during embryogenesis [86,
127]. Both receptors are present in the mesenchyme of the yolk
sac, the amnion and the chorion (7.5 days of gestation). By 9.5
days of gestation, they are expressed in the angioblasts in the
blood islands of the yolk sac, and in the endothelial cells of the
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dorsal aorta and of the perineural plexus. Subsequently, by 11.5 to
17.5 days of gestation, they are detected in most capillaries in the
developing organs such as the intersomitic regions, the heart, the
lung, the thymus, the intestines and the brain. In all these tissues
VEGF-A is expressed by adjacent cells, suggesting paracrine
regulation of VEGF-dependent blood vessel formation. In the
placenta, FLT1 and FLK1 are differentially expressed. The syn-
cytiotrophoblast cells, expressing VEGF-A and placental growth
factor (PlGF; another VEGF homologue, see below) [128, 129],
are in close proximity to the FLK1-expressing endothelium, but
further away from the FLT1-expressing spongiotrophoblast layer
[85, 86, 127]. This suggests that FLT1 may interact with soluble
VEGF-A and/or PlGF isoforms, or that other VEGF-related
ligands may interact with FLT1.
In contrast to the minimal levels of VEGF-A gene expression in
most adult tissues, VEGF-A expression is detectable in the adult
kidney, possibly implicating a role in the maintenance of endo-
thelial cell homeostasis and/or in their fenestration [56, 88]. In the
adult, VEGF-A expression can be induced by macrophages,
T-lymphocytes, astrocytes, osteoblasts, smooth muscle cells, fibro-
blasts, endothelial cells, cardiomyocytes, skeletal muscle cells and
keratinocytes [56, 88]. The expression of VEGF-A by these cells
and of its receptors by endothelial cells is significantly induced
during pathological conditions of myocardial ischemia [54], ath-
erosclerosis [130], diabetic and ischemic retinopathy [40, 55],
tumorigenesis [109, 122, 131, 132], arthritis and wound healing
[133]. This suggests that the VEGF:VEGF receptor gene family is
implicated in pathological neovascularization.
VEGF-A: transgenesis. Targeted inactivation of a single
VEGF-A allele resulted in haploinsufficiency with embryonic
lethality due to abnormal blood vessel development around 9 to
10 days of gestation [8, 9, 134]. The dorsal aorta had a much
smaller lumen. In addition, sprouting of the vessels in the
intersomitic regions, in the head mesenchyme and in the neuro-
epithelium was reduced, and connections of the large blood
vessels with the heart (in the outflow region) appeared abnormal.
In the yolk sac, large vitello-embryonic blood vessels (that connect
the yolk sac with the embryo) were absent, and only an irregular
plexus of enlarged capillaries was present. Significant vascular
defects were also present in the placenta, but hematopoiesis
appeared normal [9]. Blood vessel development was more af-
fected in homozygous VEGF-A deficient embryos, generated by
aggregation of homozygous VEGF-A deficient embryonic stem
cells with tetraploid embryos, than in heterozygous VEGF-A
deficient embryos. Expression of early endothelial cell markers
(FLK1, FLT1, TIE) was also lower in homozygous than in
heterozygous VEGF-A deficient embryos, suggesting that endo-
thelial cell development was delayed but not aborted. These data
suggest a tight gene dosage-dependent relationship and produc-
tion of only minimally required VEGF-A levels during embryonic
development. Indeed, at 8.5 days post-coitum, there were only a
few scattered endothelial cells within the homozygous VEGF-A
deficient embryo that failed to organize into a pair of dorsal
aortas. A significant VEGF-A dose dependence is also suggested
by studies involving the overexpression of VEGF-A in the devel-
oping avian embryos, resulting in the formation of a hyperfused
network of vessels, and the development of vessels in areas that
are usually avascular [90]. Overexpression of VEGF-A in the
developing chick limb bud resulted in local increases of vascular
density with no other anomalies [89], whereas conditional over-
expression of VEGF-A in implanted C6 gliomas resulted in
hemangioblastoma-like vessels [39].
Taken together, previous studies suggest that VEGF-A is not
essential for initiating the differentiation of angioblasts to early
endothelial cells, but affects further blood vessel formation at
different levels. Threshold levels of VEGF-A appear to be
required for the continued differentiation or, possibly, the survival
of endothelial cells, and for their fusion into a vessel around a
large lumen. In addition, VEGF-A affects sprouting (and proba-
bly also other forms of) angiogenesis, and controls remodeling of
emerging vessels into an interconnected network (for example, as
evidenced by the abnormal yolk sac vasculature in heterozygous
VEGF-A deficient embryos). Whether VEGF-A also affects
maturation of vessels via periendothelial cell recruitment (such as
occurs in the retina; Benjamin and Keshet, personal communica-
tion) remains to be determined.
More recently, we have used the Cre/LoxP system to generate
other VEGF-A transgenic mice that only express the VEGF-A120
isoform. Initial analysis indicates that homozygous VEGF-A120
embryos die shortly after birth, possibly because of ischemic
cardiomyopathy and increased vascular fragility and hemorrhag-
ing in several tissues. Thus, VEGF-A120 is able to rescue the
defective embryonic vascular development of heterogygous
VEGF-A deficient embryos, but appears to be insufficient to
sustain a functional vasculature in a homozygous form (unpub-
lished observations in collaboration with P. d’Amore et al, Har-
vard Medical School, Boston, MA, USA). In addition, a trans-
genic mouse model of intra- and subretinal neovascularization
was generated by overexpression of VEGF-A in the photorecep-
tors [135]. This may allow the study of the role of VEGF-A in the
pathological neovascularization during diabetic and ischemic ret-
inopathy.
VEGF-A: Regulation by hypoxia. Hypoxia is an important regu-
lator of angiogenesis. In contrast to the other VEGF homologues
PlGF, VEGF-B and VEGF-C (see below), which are unrespon-
sive or are even inhibited by hypoxia [136–139], expression of
VEGF-A is markedly up-regulated by hypoxia [54]. Hypoxic
regulation of VEGF-A gene expression is mediated by hypoxia-
inducible factors (HIFs). To date, HIF-1a [140, 141]), HIF-2a
(also named EPAS-1, HRF or HLF [140, 142–144]), and HIF-1b
(or ARNT) [140, 141]) have been identified, which bind an
enhancer HIF-response element in the promoter region of
VEGF-A. In addition, hypoxia stabilizes the VEGF-A mRNA
through interaction of RNA binding proteins with sequences in
the 39 untranslated region [54]. The von Hippel-Lindau gene
product has been implicated in the latter process [145]. We and
others have embarked on targeting and inactivating these hy-
poxia-inducible factors that regulate VEGF-A gene expression.
For example, embryos deficient in the arylhydrocarbon-receptor
nuclear translocator (ARNT) die around 10.5 days of gestation
due to defective vascular development, similar to that in VEGF-A
deficient embryos [35]. However, different from the latter, vascu-
lar defects were observed in the yolk sac and in some, but not in
all regions within the embryo proper. Aryl hydrocarbon receptor
nuclear transport (ARNT)-deficient embryonic cells produced
significantly less VEGF-A under hypoxia. Somatic ARNT-defi-
cient cells also had an impaired hypoxic induction of gene
expression and failed to develop highly vascularized tumors in vivo
[146]. In another ARNT inactivation study, ARNT deficient
embryos died around 10 days of gestation due to placental
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hemorrhaging, delayed and abnormal neurogenesis and visceral
arch development [36]. Despite seemingly normal chorio-allantoic
fusion, the chorionic capillary plexus was underdeveloped. The
yolk sac vasculature, however, appeared normal. Since ARNT is
coexpressed with VEGF-A in the trophoblast giant cells of the
developing placenta, it is conceivable that loss of ARNT gene
function reduced VEGF-A levels to below the critical threshold
required for proper vascular development in the placenta [36, 85].
Alternatively, or additionally, VEGF-A levels may have been
insufficient to provide an autocrine survival or differentiation
function for the trophoblasts [128]. It remains to be determined
whether the neural defects are secondary to the placental and
circulatory defects, or related to the impaired heterodimerization
with other ARNT partners.
Deficiency of the von Hippel Lindau (VHL) gene resulted in
embryonic lethality around 10.5 to 12.5 days of gestation due to
abnormal vascularization in the placenta [37]. VHL is primarily
expressed in the labyrinth trophoblasts, in the allantoic mesoderm
and in some embryonic endothelial cells in the placenta. At a
lower level, VHL is expressed in the yolk sac visceral endoderm
and in other regions within the embryo proper around 10.5 days of
gestation. VEGF-A is also expressed at several of these sites (see
above). Both mutant embryo and placenta developed normally
until 9.5 days of gestation. At the time of chorioallantoic fusion
and expansive growth of the placental labyrinth, VHL deficient
embryos lacked embryonic blood vessels in the placental laby-
rinth, but presumably the embryo proper appeared normal. The
trophoblasts failed to develop into syncytiotrophoblasts, and by
11.5 to 12.5 days the placental labyrinth showed great disruption,
loss of normal structure, necrosis and hemorrhage. In addition,
the yolk sac in some embryos appeared atrophic and had reduced
numbers of blood islands. Surprisingly, immunocytochemical
VEGF-A levels in the placental labyrinth trophoblasts at 10.5 days
were reduced in the mutant embryos, contrary to the expectation
that loss of an inhibitory regulator of VEGF-A expression would
increase VEGF-A expression levels. In summary, VHL appears to
play an essential role in vasculogenesis in certain but not in all
embryonic regions, and the consequences of its gene loss appear
to correlate with its level and pattern of expression. An intriguing
question is whether hypoxic regulation of VEGF-A expression by
VHL is opposite to that in renal carcinoma cell lines.
Initial analysis of embryonic stem cells lacking HIF-1a reveals
that hypoxic or hypoglycemic induction of several target genes
(VEGF-A, phosphoglycerokinase, lactate dehydrogenase) is sig-
nificantly reduced to absent when cells were cultured as embryoid
bodies or monolayers in vitro (unpublished data, in collaboration
with Y. Dor and E. Keshet). In addition, HIF-1a deficient
teratocarcinomas were significantly more avascular when grown in
nude mice in vivo. Taken together, these data imply important
roles for hypoxia-inducible mechanisms in control of angiogenic
factors and blood vessel formation in vivo.
VEGF-A (gene) therapy. VEGF-A (gene) therapy has been used
to improve blood flow in ischemic limbs and in the myocardium
[58, 147, 148]. Interestingly, the neovascularization response
appears to be restricted to the ischemic tissues, possibly because
of specific up-regulation of VEGF receptors by hypoxia [149, 150].
Although VEGF-A treatment of ischemic myocardium increases
capillary density, it also increases the number of muscular distri-
bution vessels, presumably via the production of PDGF by the
VEGF-activated endothelium [116]. Nitric oxide may mediate the
VEGF-A angiogenic response, as VEGF-A induces release of
nitric oxide [118], and nitric oxide synthase blockers or gene
deletion impairs neovascularization in the ischemic limb despite
similar VEGF-A expression [60]. VEGF-A may also increase
blood flow and tissue reoxygenation by causing nitric oxide-
dependent vasodilation [117, 151].
VEGF-A has been used with variable success to improve
reendothelialization of denuded vessels, and to reduce arterial
stenosis after injury [152, 153]. The latter may be due to “silenc-
ing” of the activated intimal smooth muscle cells by regrowing
endothelial cells. Alternatively, endothelial nitric oxide (induced
by VEGF-A) may inhibit platelet aggregation and smooth muscle
cell proliferation, and in addition increase the overall vessel size
by vasodilation. In a negative feedback loop, nitric oxide may shut
down VEGF-A expression after reendothelialization has been
completed and endothelial cells have regained their quiescent
state [154]. Anti-VEGF-A (gene) therapy, whether by immuno-
neutralization, antisense gene inhibition or transfer of dominant
negative VEGF receptors or VEGF chimeric toxins (VEGF165
cross-linked to diptheria toxin), is an effective means to suppress
neovascularization during cancer and diabetic retinopathy [55, 56,
155–157].
Placental growth factor (PlGF). More recently, other VEGF-
related factors with a conserved pattern of eight cysteine residues
have been identified. The latter may form intra- and interchain
disulfide bonds, generating biologically active antiparallel dimeric
molecules similar to PDGF. Homo- or heterodimerization of
these ligands may determine their biological specificity [158–160].
Placental growth factor (PlGF) is expressed in the placenta and,
to a lesser extent, in the heart, lung and the thyroid gland [128,
161, 162]. PlGF is variably expressed in tumors [137, 163]. In the
placenta, PlGF may act in an autocrine fashion on trophoblast
growth and differentiation, as mRNA synthesis of both PlGF and
its receptor FLT1 occur in the villous trophoblasts and syncy-
tiotrophoblasts [128, 129]. Since these cells also produce
VEGF-A, PlGF and VEGF-A may form heterodimers. Moderate
immunostaining of PlGF was evident in the endothelial cells lining
the villi and in the media of larger blood vessels [128]. Three
alternatively transcribed PlGF mRNAs have been identified in
humans, of which the longest form has an affinity for extracellular
matrix components [129, 161, 162, 164]. Although the role of
PlGF homodimers on endothelial cell proliferation is controver-
sial, it may, via interaction with VEGF-A, modulate the mito-
genic, chemotactic and vascular permeability-inducing properties
of the latter [136, 158–160, 165, 166]. PlGF129/VEGF-A165 het-
erodimers induced corneal neovascularization with a maximal
vessel length similar to VEGF-A165, but with a marked decrease
of vessel density, consistent with the observations that these
heterodimers were equally potent in stimulating endothelial mi-
gration but 20- to 50-fold less mitogenic than the VEGF-A165
homodimers [167, 168]. PlGF may also affect the angiogenic
response indirectly by stimulating monocyte recruitment [111].
Notably, in contrast to the marked hypoxic up-regulation of
VEGF-A by hypoxia, PlGF expression is not affected or even
slightly reduced by hypoxia [136, 137]. Nevertheless, because
hypoxia induces the expression of VEGF-A, the formation of
PlGF/VEGF heterodimers is under hypoxic control [167, 168].
Deficiency of PlGF in transgenic mice did not compromize
development, feritility or placentation (unpublished observations
in collaboration with G. Persico et al, Naples, Italy). This was not
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anticipated in view of the presumed role of PlGF in establishing
vascular connections in the placenta. However, initial analysis
suggests that healing of skin wounds, formation of granulation
tissue, and vascular permeability after topical VEGF-A applica-
tion are abnormal.
VEGF-B. VEGF-B has similar endothelial mitogenic potency as
VEGF-A, and is primarily expressed in the heart, the skeletal
muscle, the brain and the kidney [169]. VEGF-A and VEGF-B
are co-expressed in many tissues and are able to heterodimerize
with each other. VEGF-B remains largely cell-associated, possibly
providing spatial cues to outgrowing endothelial cells, or acting as
a releasable pool to induce endothelial cell regeneration after
injury. Expression of VEGF-B is not responsive to hypoxia,
PDGF, TGF-b1 or epidermal growth factor, and in fact, the
half-life of VEGF-B mRNA is unusually stable (.8 hr), suggest-
ing chronic rather than acute regulation [139]. Recent data
suggest that VEGF-B deficient mice develop normally and are
healthy (Alitalo et al, personal communication).
VEGF-C. VEGF-C (also called VEGF-related factor: VRP; or
VEGF-2) stimulates migration and proliferation of endothelial
cells, although with a lower potency than VEGF-A [119, 170–
172]. At high doses, VEGF-C is able to interact with the VEGF
receptor-2 or FLK1 [170, 172]. In the adult, it is most abundantly
expressed in the heart, the placenta, the lung, the kidney, the
muscle, the ovary and the small intestine. During embryonic
development, VEGF-C is first detectable around 8.5 days of
gestation in the cephalic mesenchyme, along the somites, in the
tail region, and in the allantois [170, 172]. The VEGF-C receptor
(VEGF receptor-3 or FT4; see below) is expressed at sites
immediately adjacent to those of VEGF-C expression, such as in
the angioblasts of the head mesenchyme, between the developing
somites, in the allantois, and in the endothelial cells of venous
lacunae in the placenta, but not in the blood islands of the yolk sac
[80, 172]. In 12.5-day-old embryos, VEGF-C mRNA is particu-
larly abundant in the anterior paravertebral and intervertebral
tissues, whereas FLT4 expression is high in the adjacent anterior
veins and intervertebral vessels. Similar paracrine coexpression of
VEGF-C and FLT4 was observed around the developing meta-
nephros, and, at lower levels, in the lung and in the cephalic
region. Taken together, these findings indicate that VEGF-C and
FLT4 may initially be involved in the development of the venous
system, whereas at later periods, they colocalize in the perineph-
ric, mesenterial and jugular regions where the first lymphatic
vessels sprout from venous sac-like structures. Mice overexpress-
ing VEGF-C in the skin specifically develop hyperplasia of
lymphatic vessels [173]. Since VEGF-C binds to both FLK1 and
FLT4, the specific effect of VEGF-C on lymphatic and not on
endothelial cell function may relate to a requirement for het-
erodimerization of both receptors. Deficiency of VEGF-C (as well
as of FLT4) results in early embryonic lethality, the precise cause
of which needs to be further determined (K. Alitalo, personal
communication).
VEGF-D. FIGF (also called VEGF-D) is a VEGF homologue,
cloned by differential display between normal and c-fos knockout
mouse fibroblasts [174]. It was independently retrieved from EST
libraries as a VEGF homologue, with close structural relationship
to VEGF-C [175]. VEGF-D gene expression is induced by c-fos
and is more abundant in serum-starved quiescent cells, similar to
the expression of the growth-arrested gas-6 gene [174]. In vivo,
VEGF-D is expressed abundantly in the lung, the heart, the small
intestine, and the fetal lung. It was also expressed at lower levels
in skeletal muscle, in the colon and the pancreas [175]. Expression
in tumor lines was undetectable. Although the structural similar-
ities between VEGF-C and VEGF-D suggest similar functions,
their expression patterns differ (for example, VEGF-D is more
abundantly expressed in the lung than VEGF-C) [175]. Although
VEGF-D is able to induce proliferation and morphological trans-
formation of fibroblasts [174], its possible effects on endothelial
cells, and its regulation by hypoxia remain to date unknown. The
differential role of these VEGF homologues in governing vascular
development during embryonic development or adult pathology is
largely unkown.
VEGF receptors. Three receptor tyrosine kinases with seven
immunoglobulin domains, which bind the VEGF family members
with different specifity and affinity, have been identified thus far
[87]: the VEGF receptor-1 (VEGFR-1or FLT1) binds VEGF-A
and PlGF [160, 165, 176], the VEGF receptor-2 (VEGFR-2 or
FLK1) binds VEGF-A and VEGF-C (possibly with a lower
affinity, although this is controversial) [170, 177], and the VEGF
receptor-3 (VEGFR-3 or FLT4) binds VEGF-C [170, 178]. In
addition, low-affinity surface-associated receptors that selectively
bind VEGF-A165 via the exon 7-encoded domain have been
identified in certain tumor cells [179]. A receptor for VEGF-D
has not been characterized yet, but because of its structural
similarities to VEGF-C, FLT4 may be a candidate. It has been
suggested that the stability of VEGF-heparan sulfate-receptor
complexes contributes to effective signal transduction. Following
stimulation with VEGF-A, FLK1 overexpressing endothelial cells
undergo changes in cell morphology, actin reorganization, mem-
brane ruffling, chemotaxis and mitogenicity, whereas FLT1 over-
expressing cells lack such responses [123, 180]. FLK1 is autophos-
phorylated upon stimulation of intact endothelial cells with
VEGF-A and VEGF-C [170, 181], whereas FLT1 is only phos-
phorylated in vitro in response to VEGF-A [181]. Recent evidence
suggests, however, that FLT1 is a signaling receptor in monocytes,
involved in their chemoattraction [111], and in trophoblasts,
mediating nitric oxide release [128]. FLT4 is autophosphorylated
upon binding of VEGF-C, but not of VEGF-A or PlGF [170, 171].
The second Ig-like domain of FLT1 contains critical determinants
required for the interaction with VEGF-A and PlGF [182]. These
results suggest that FLK1 and FLT4, but not FLT1, confer the
mitogenic potential of VEGF-A and VEGF-C to endothelial cells.
Alanine-scanning mutagenesis of VEGF-A confirmed this hy-
pothesis, since VEGF-A mutants lacking FLK1 affinity are not
mitogenic, whereas VEGF-A mutants with reduced FLT1 affinity
induce normal endothelial cell proliferation [72].
Deficiency of the VEGF receptor FLK1 resulted in embryonic
lethality around 10 days of gestation due to abnormal vascular
development [14]. Histological examination revealed complete
absence of organized blood vessels and necrosis in the mutant
embryo proper. More recent analysis of chimeric wild type 7
homozygous FLK1 null mutant mice indicated that endothelial
cells were always wild-type, demonstrating a cell-autonomous
requirement for FLK1 in endothelial cell differentiation [183]. In
addition, FLK1 appears to ensure the recruitment of mesodermal
precursors from the posterior primitive streak to the yolk sac,
where they differentiate into endothelial progenitors. LacZ ex-
pression (by the targeted FLK1 promoter) was only detected in
putative endothelial cell precursors. Thus, the developing meso-
derm cannot complete differentiation into blood islands in the
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absence of a functional receptor. Interestingly, the observation
that VEGF-A deficiency did not result in a similar phenotype as
the FLK1 deficiency suggests the presence other VEGF-related
ligands for FLK1 (possibly VEGF-C [170, 172]), or rescue by
maternal VEGF-A.
Targeting of the FLT1 gene also resulted in embryonic lethality
around 10 days of gestation [15]. Staining for LacZ (expressed by
the targeted FLT1 promoter) revealed the presence of numerous
differentiated endothelial cells, which, however, failed to form an
organized vascular network. These vascular structures were ab-
normally large and fused, and contained enclosed LacZ positive
endothelial cells. These findings suggest a possible role of FLT1 in
contact inhibition of endothelial cell growth, or in endothelial cell
assembly via controlling adhesion between endothelial cell pre-
cursors.
Endothelial cell receptor tyrosine kinase TIE1
TIE1 (tyrosine kinase with immunoglobulin and epidermal
growth factor homology domains) and TIE2/TEK (tunica interna
endothelial cell kinase) comprise another family of endothelial
cell specific receptor tyrosine kinases [184–186]. Ligands have
been only identified for the TIE2 receptor: the agonist angiopoi-
etin (ANG)-1 [187] and the antagonist ANG2 [24]. Although both
TIE1 and TIE2 are expressed by endothelial cells, TIE1 is
implicated in endothelial cell function, whereas the ANG/TIE2
signaling system appears to primarily affect blood vessel forma-
tion via an effect on periendothelial cells (and is therefore
discussed in the next section).
Low levels of tie1 mRNA first become evident at 8.0 days of
gestation in the extraembryonic mesoderm shortly after formation
of the yolk sac blood islands [22, 184, 185]. By 8.5 days, tie1
mRNA is expressed in the heart, the paired dorsal aortae and the
allantois but not in the amnion, whereas by 9.5 days tie1 is also
expressed in the intersomitic vessels as well as in the smaller head
mesenchyme vessels. The migrating endothelial cells in the devel-
oping heart are also positive for tie1. Later during development,
tie1 mRNA is expressed in virtually all endothelial cells of the
embryo proper [22]. In adult mice, the expression of tie1 persists
in vessels of the lung, whereas in the brain, the heart and the liver,
its expression levels are down-regulated. Newly formed capillaries
in ovaries and in the granulation tissue of skin wounds and tumors
display induced tie1 expression levels [184].
Targeted inactivation of the tie1 gene resulted in normal
differentiation of the endothelium, and formation and patterning
of early blood vessels by 13 days of gestation [22]. However, within
one day, homozygous TIE1-deficient embryos manifested hemor-
rhages distributed throughout the body surface, became edema-
tous and died by 14 days of gestation. Upon microscopic analysis,
most large blood vessels appeared normal but staining for LacZ
(expressed by the targeted tie1 promoter) was reduced in the
microvasculature, often associated with breakdown of the vessel
integrity and hemorrhage. In another tie1 gene inactivation study,
only a fraction (15%) of homozygous TIE1 mutant embroys died
at 13 days of gestation due to localized hemorrhage and edema
[21]. The remainder fraction of mutant embryos displayed severe
edema and hemorrhage at multiple locations throughout the body
one day prior to birth, and died immediately after birth due to
respiratory problems resulting from pulmonary congestion. De-
spite a normal vessel pattern, the structural integrity of the
endothelial cells in the mutant embryos was defective, as revealed
by the extravasation of erythrocytes through, but not between
endothelial cells. Blood vessels in chimeric wild-type 7 homozy-
gous TIE1 null mutant mice initially (10.5 days of gestation)
contained TIE1 deficient endothelial cells, but at 15.5 days of
gestation, TIE1 deficient endothelial cells were significantly un-
derrepresented in sprouting vessels in the brain and in the kidney
[188]. In the adult, TIE1 endothelial cells became progressively
absent, suggesting a cell-autonomous requirement for TIE1 in
angiogenic rather than in vasculogenic blood vessel formation.
Thus, the “leaky syndrome” of the TIE1 deficient embryos
suggests that TIE1 is not required for early endothelial cell
differentiation, vasculogenesis and the initial steps of angiogene-
sis. TIE1 appears, however, to be required for the structural
integrity of microvascular endothelial cells, the control of fluid
across capillaries, or the hemodynamic stress resistance during
maturation of blood vessels.
In a more recent study, lack of the TIE1 receptor was found to
cause an increase in the number of vessels throughout the embryo.
This resulted in a denser, more complex and malformed vascular
network, with associated tissue abnormalities (increased number
of glomeruli, thicker alveolar septa, more plump and connected
intestinal folds) [25]. This appeared to result from uncontrolled
vessel remodeling, as the number of endothelial cells was unaf-
fected. Ultrastructurally, TIE1 deficient endothelial cells were
“hyperactive,” exhibiting a larger number of extensions and
filopodia projecting into the vessel lumen. Notably, periendothe-
lial cells were numerous, but the intussusceptive folds contained
less interstitial collagen. These data suggest that TIE1 plays a
crucial role in endothelial cell extensions and stretching, ulti-
mately resulting in membrane fusion of opposing cells and
intussusceptive growth. In the absence of TIE1, endothelial cells
are stretched, appear hyperactive and form intra- and transcellu-
lar holes, responsible for the increased leakiness and edema.
Taken together, these more recent data suggest that a major
function of TIE1 is to prevent excessive vascular branching via
intussusceptive growth.
Fibroblast growth factors
Fibroblast growth factors (FGF) belong to a family of at least
nine members that bind four distinct high-affinity cellular recep-
tors with tyrosine kinase activity [189–191]. Several receptor
isoforms, generated by alternative splicing and internal polyade-
nylation, differ in their specificity and affinity for their ligands, and
in their intracellular tyrosine kinase domains. In addition, distinct
heparan sulfate proteoglycans (syndecans, glypican) provide low-
affinity binding sites, which mediate or influence binding to
high-affinity receptors. The physiological mechanims of release of
acidic FGF (aFGF or FGF1) and of basic FGF (bFGF or FGF2),
which both lack a conventional leader sequence, remain enig-
matic. It is unclear whether they can be secreted from intact cells,
or whether they are only liberated after (non)-lethal injury
(possibly via the use of ischemia-induced heat-shock proteins as
chaperones [192]) or from dying cells. FGF1 and FGF2 have been
implicated in the growth and the differentiation of a variety of
mesodermal or mesectodermal tissues. In vitro, FGF2 (and to a
certain extent also FGF1) stimulates endothelial cell migration,
proliferation, release of proteolytic enzymes and capillary tube
formation [69, 189–191]. FGF2 induces mesoderm in the avian
embryo to differentiate in vitro to angioblasts [7]. FGF2 is
detectable in the subendothelial basement membrane of blood
vessels, where it is stored in the extracellular matrix as a reservoir
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of inactive peptide, requiring liberation by matrix proteinases or
heparin [193, 194]. In vivo, expression of FGF2 frequently colo-
calizes with sites of active blood vessel growth, such as within
atherosclerotic plaques or in tumors [195].
Nevertheless, the physiological relevance of FGF2 signaling for
vascular development during embryogenesis has remained con-
troversial. Indeed, although FGF2 is expressed at low levels
throughout initial embyrogenesis, its expression pattern does not
correlate with brain angiogenesis [196], and as yet, FGF2 recep-
tors have not been convincingly detected on endothelial cells or
angioblasts in vivo. Notably, mice deficient in FGF2 exhibit no
overt vascular abnormalities, although it is not known whether
these may be affected by maternal transfer (Doetschman et al,
personal communication). However, adenoviral antisense FGF2
gene transfer in cultured 8.5-day-old murine embryos disrupts the
formation of a remodeling vascular bed in the yolk sac and
prevents vascular connections between the yolk sac and the
embryo proper ([197], and C. Buck, personal communication).
These apparently contradictory results may be reconciled by
postulating that the role of FGF2 during mesoderm induction and
subsequent vascular development is redundant in the mouse (but
perhaps not in the avian embryo). Alternatively, it is possible that
the conditional FGF2 gene inactivation has revealed a role of
FGF2 during embryonic vessel formation, which was obscured by
compensatory processes in the FGF2 null embryos. An unresolved
issue is also whether FGF2 affects periendothelial cell function
during embryonic vascular development. Indeed, FGF2 mediates
the mitogenic effect of thrombin on vascular smooth muscle cells
during the hyperplastic response of the injured artery, and
influences serum-induced smooth muscle cell proliferation [198,
199].
In the adult, administration of FGF2 induces directed ingrowth
of new capillaries in corneal implants and in skin wounds, and
promotes re-endothelialization of denuded vessels in vivo [200].
Indirect evidence further suggests that FGF2 is implicated in the
prenatal and early postnatal coronary development [48, 57].
Initially, the developing heart tube is avascular, and only endo-
thelial cells line the endocardium. As the wall of the heart
thickens, the endocardial surface becomes progressively more
trabeculated, thereby establishing a system of endocardial-lined
sinusoids that minimizes diffusion distances [47, 59, 201]. Around
midgestation, endothelial progenitor cells (angioblasts) migrate
from the region of the liver and the septum transversum to the
heart and populate the epicardium. These angioblasts differenti-
ate in situ into endothelial and hematopoietic precursors, which
subsequently form a primitive capillary plexus (vasculogenesis).
FGF1 and FGF2 are highly expressed in the heart (cardiomyo-
cytes, endothelial cells, fibroblasts) around this period [196]. In
addition, FGF2 stimulates capillary tube formation from myocar-
dial explants, suggesting an involvement of FGF2 in myocardial
vascularization. During the first weeks after birth, the high FGF2
levels may also be involved in the marked capillary growth. The
latter occurs as a result of the increased metabolic needs of the
heart (due to the closure of the ductus arteriosus, the pressure
load on the left ventricle increases). A role for FGF2 in myocar-
dial angiogenesis is further suggested by evidence that protamine-
mediated block of FGF receptor binding decreases postnatal
capillarization.
Administration of FGF2 increases the number of capillaries in
the infarcted myocardium, but not in the non-ischemic heart
regions. This may be due to the hypoxic up-regulation of FGF
receptors and of other growth factors with known properties to
modulate new blood vessel formation (TGF-b1, interferon-a,
interleukin-2 and PDGF) [58, 202–205]. FGF2, endogenously
produced by invading macrophages, may also exert such an
angiogenic response [67]. The beneficial effect of FGF2 on
collateral reserve and cardiac function, however, may not be
restricted to an effect on endothelial cells only, but also on smooth
muscle cells and cardiomyocytes (see below). That FGFs affect
multiple cell types is further evidenced by the observation that in
vivo gene transfer of a secreted FGF1 in the vessel wall induces
intimal smooth muscle cell accumulation in addition to neocapil-
lary formation [206]. Unlike FGF2, FGF5 possesses a leader
sequence, and intracoronary adenoviral FGF5 gene transfer im-
proves blood flow and cardiac function [207]. Since the number of
collateral vessels did not dramatically increase, FGF5 may have
recruited pre-existing collateral vessels via nitric oxide-mediated
vasodilation. Such a mechanism may be especially relevant during
ischemia, as the microcirculation in the ischemic areas appears to
be more sensitive to FGF- (and to VEGF-; see above) mediated
vasodilation by nitric oxide [203]. In aggregate, although admin-
istration of FGFs may induce blood vessel formation, definite
functional proof for a role of the endogenous FGFs in embryonic
or adult vessel formation awaits further study.
Extracellular matrix proteins
Extracellular matrix proteins influence tissue architecture and
interactions. In addition, they may also affect cell proliferation,
migration, differentiation and transformation, for example by
sequestering a variety of growth factors (FGFs, TGFb, PDGF),
the bioavailability of which requires proteolytic liberation [194,
208]. Extracellular matrix, both in the stroma and in the basement
membranes, is composed of fibers such as collagen and elastin,
and a diffuse “ground substance” of multiple forms of carbohy-
drates and glycoprotein moieties. The basement membrane con-
sists of a lamina lucida, the lamina densa (or the basal lamina),
and the lamina fibroreticularis, the latter containing fine fibrils
that connect the basal lamina with the underlying stroma [209].
The basal lamina is composed of collagen IV, laminin, heparan
sulphate proteoglycan (perlecan), nidogen (entactin) and other
components such as fibulin and osteonectin. Interactions between
laminin (of which at least 7 different isoforms exist), collagen IV
and perlecan are mediated via nidogen [210], and result in the
formation of stabilizing ternary complexes [211]. Nidogen may,
however, also control matrix breakdown because of its unusual
sensitivity to proteolytic degradation by matrix metalloproteinases
and plasmin [212]. Because endothelial cells produce both nido-
gen and laminin in stochiometric amounts, ternary complexes with
collagen IV and perlecan are rapidly formed, causing their
basement membranes to be very stable and higly resistant to
proteolysis. In contrast, basement membranes that form at the
interface of mesenchymal and epithelial cells, or around mesen-
chymal cells, are more soluble and susceptible to proteolysis,
because variations in the production of any one basement mem-
brane component by either cell type prevent stable ternary
complex formation. These differences in basement membrane
structure may determine processes such as branching or sprouting
[211]. Indeed, because laminin-1 and nidogen are coexpressed by
the mesenchymal cells in the proximal bronchial regions, their
basement membrane is more stable and proteolysis-resistant than
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that in the distal lobules, where nidogen is expressed by the
mesenchymal cells and laminin-1 by the epithelial cells. Conse-
quently, remodeling and branching of the distal lung buds is
promoted. It remains unknown to what extent vascular sprouting
is also regulated by such processes, although differentiation of
angioblasts to endothelial cells involves a change in integrin
expression, and a switch from a mesenchymal- to an endothelial-
specific laminin [213]. The next discussion will review those
extracellular matrix components that appear to play a primary
role during endothelial tube formation (as deduced from gene
targeting studies), whereas those that are involved during smooth
muscle cell assembly are discussed in the next section.
Fibronectins are widely present during early embryonic vascular
development and precede the deposition of laminin and collagen
IV [214]. It was therefore not surprising that development of the
heart and the embryonic vasculature in fibronectin deficient
embryos was severely abnormal, resulting in lethality around 10
days of gestation [10, 215]. Fibronectin appears to be necessary for
normal vasculogenesis, as the blood islands in the yolk sac fail to
develop into a primary network of capillaries, in part because the
visceral endoderm layer separates from the mesoderm layers. Due
to the increased fragility, the primary capillary vessels rupture
within each other and break open, inducing leakage of blood into
the extracoelomic cavity. Intraembryonic vessel formation was
also abnormal, as evidenced by the lack or abnormal distention of
the dorsal aortae. These results indicate that fibronectin plays
important roles in the development and integrity of blood vessels.
A general deficit in mesoderm formation due to impaired adhe-
sion, migration and/or proliferation could underly these vascular
defects. It remains, however, unknown to what extent endothelial
or periendothelial cells (which also produce fibronectin) are
affected and contribute to the vascular defects.
Cell-matrix interactions occur by both integrin and non-integrin
cell surface receptors, leading to changes in cytoskeletal organi-
zation, cell shape and intercellular junctions, in addition to
transducing signals regulating gene expression [216, 217]. Endo-
thelial cells possess integrin receptors for fibrinogen, collagen I,
collagen IV, laminin, fibronectin, and vitronectin. At least eight
integrins bind to fibronectin, although not all are expressed on
similar cell types. Deficiency of the a5 integrin subunit (which
mediates binding of fibronectin via the a5b1 integrin) results in
embryonic lethality around 10 to 11 days of gestation, and is
associated with abnormal formation of the dorsal aorta. The
vitelline vessels are fragile and aneurysmally dilated due to
separation of the yolk sac layers, leak and ultimately rupture with
fatal bleeding [11]. These mutant embryos show a less severe
phenotype than the fibronectin null embryos, suggesting that
other receptors suffice to support fibronectin function in vascular
development.
VCAM-1 is a cytokine-inducible endothelial cell surface pro-
tein capable of mediating adhesion of leukocytes to a4 integrin
during inflammatory processes, such as during allograft rejection
and atherosclerosis. Unexpectedly, loss of VCAM-1 resulted in
embryonic lethality (in 50% of the embryos) around 11 days of
gestation due to severe placental defects in which the allantois
failed to fuse with the chorion [28, 29]. The remaining VCAM-1
deficient embryos died one day later due to cardiac malformation.
The epicardium was abnormal to absent. Since the epicardial
primary capillary plexus is derived from the epicardium [47], its
abnormal development may have contributed to defects in coro-
nary vessel formation and pericardial hemorrhaging. In addition,
the compact layer of the ventricular myocardium and the intra-
ventricular septum were significantly thinner, perhaps secondary
to the defective myocardial angiogenesis. Embryos lacking the a4
integrin [30] phenocopy the VCAM-1 deficient phenotype. This is
not surprising given the reciprocal expression of VCAM-1 in the
chorionic plate and the myocardium, and of the a4 integrin in the
allantois and the epicardium, respectively. Since the a4 integrin
mediates cell-matrix and cell-cell adhesions by interacting with
fibronectin and VCAM-1, respectively, and since fibronectin null
embryos did not reveal placentation defects, it is unlikely that
fibronectin mediated the fusion of the chorio-allantois. Thus,
VCAM-1 and the a4 integrin play roles in the fusion of endothe-
lial cells, which are required to establish a vascular connection
between the embryonic and maternal tissues. However, it remains
to be determined to what extent pericytes, which also express
VCAM-1 [218], participate in this process. Indeed, since these
periendothelical cells may precede rather than follow endothelial
sprouts, they could significantly affect chorio-allantoic fusion.
Deficiency of the a3 integrin in mice resulted in perinatal death
with severe abnormalities in the kidneys and the lungs of mutant
newborn mice [219]. Glomerular podocytes lacked foot processes
and the glomerular basement membrane appeared fragmented
and disorganized. There were fewer and wider glomerular capil-
lary loops. Since glomerular endothelial cells express the a3b1
integrin (a receptor for nidogen/entactin), the vascular defects
may result from a primary defect in endothelial tube formation, or
be a consequence of the failure of the podocytes to provide an
adequate scaffolding within which the capillaries would develop.
Vitronectin is expressed during embryogenesis in the liver, the
nervous system and in a subpopulation of endothelial cells [220].
In the adult, it circulates in the plasma at high levels. Surprisingly,
deficiency of vitronectin did not result in overt vascular anomalies,
suggesting a redundant role during embryonic vascular develop-
ment [34]. Recently, the avb3 integrin (a vitronectin receptor) has
been identified as a marker of the angiogenic phenotype [98]. It is
predominantly expressed on growing and migrating endothelial
cells in wound granulation tissue but not in normal skin. In
addition, its expression was up-regulated in chick chorioallantoic
membrane during angiogenesis induced by FGF2, TNF-a, and
tumor fragments [221]. Monoclonal antibodies to avb3 integrin
blocked the sprouting of angiogenic vessels, but did not affect the
pre-existing vessels [99], consistent with its minimal expression on
quiescent endothelial cells in normal tissues. At least part of the
role of the avb3 integrin may be related to an endothelial cell
survival function [45]. Another vitronectin receptor, the avb5
integrin, appears to be involved in VEGF-induced angiogenesis.
Peptide antagonists of avb3 and avb5 integrins significantly inhib-
ited the neovascularization response induced by cytokines or
during retinal ischemia [222]. Surprisingly, loss of the av integrin
gene function does not appear to compromise early vascular
development, but to induce vascular fragility with associated
bleeding in the brain later during development (R. Hynes et al,
personal communication). This is in apparent contradiction to the
severe effect of immunoneutralizing avb3 integrin antibodies in
the avian embryo, which prevented lumen formation of the aorta,
induced vascular leaks via discontinuation of the endothelial
lining, and promoted aberrant vascular patterning [16]. This
resulted from impaired endothelial cell spreading and reduced
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formation of endothelial protrusions. It remains to be determined
whether these differences in the mouse and avian embryo are due
to functional redundancy between integrins during embryonic
vascularization, or whether the role of the av integrin can only be
revealed by conditional immunoneutralization, or is different
between species. In aggregate, the various extracellular matrix
proteins exert distinct and specific roles during the development
of new blood vessels, and their importance during embryogenesis
or adulthood significantly varies.
Extracellular matrix proteinases
Movement of endothelial cells involves proteolysis of the
extracellular matrix. Two families of matrix degrading protein-
ases, the plasminogen activator (PA) and the matrix metallopro-
teinase (MMP) system, can, in concert, degrade most extracellular
matrix proteins. The plasminogen system is composed of an
inactive proenzyme plasminogen (Plg) that can be converted to
plasmin by either of two plasminogen activators (PA), tissue-type
PA (t-PA) or urokinase-type PA (u-PA) [223, 224]. This system is
controlled at the level of plasminogen activators by plasminogen
activator inhibitors (PAIs), of which PAI-1 is believed to be
physiologically the most important [225–227], and at the level of
plasmin by alpha2-antiplasmin [223]. Due to its fibrin-specificity,
t-PA is primarily involved in clot dissolution [223, 224]. u-PA
binds a cellular receptor (u-PAR), and has been implicated in
pericellular proteolysis during cell migration and tissue remodel-
ing during angiogenesis, atherosclerosis and restenosis [68, 228].
Plasmin is able to degrade fibrin and extracellular matrix proteins
directly or, indirectly, via activation of other proteinases (such as
the metalloproteinases) [71, 229, 230]. Plasmin can also activate
or liberate growth factors from the extracellular matrix including
latent TGB-b1, FGF2, IGF-1 and VEGF-A [56, 71–73].
Matrix metalloproteinases (MMPs) constitute a family of pro-
teinases able to degrade most extracellular matrix components in
the vessel wall [69, 231, 232]. In the mouse, MMP-13 (collagenase
3) is the primary interstitial collagenase, whereas MMP-2 (gela-
tinase A) and MMP-9 (gelatinase B) degrade collagens type IV,
V, VII and X, elastin and denatured collagens. The stromelysins-1
and -2 (MMP-3 and MMP-10) and matrilysin (MMP-7) break
down the proteoglycan core proteins, laminin, fibronectin, elastin,
gelatin and non-helical collagens, while the macrophage met-
alloelastase (MMP-12) primarily degrades insoluble elastin in
addition to collagen IV, fibronectin, laminin, entactin and proteo-
glycans. The membrane-type metalloproteinases (MT1-MMP and
MT2-MMP) activate gelatinase-A. Control of MMP activity is
mediated by tissue inhibitors of MMPs (TIMPs) in a tissue- and
substrate-specific manner. Since MMPs are secreted as zymogens,
they require extracellular activation. u-PA-generated plasmin is a
likely pathological activator of several zymogen MMPs [230].
Quiescent endothelial cells constitutively express t-PA, MMP-2
and minimal MMP-1 [69, 223, 224]. Net proteolysis is, however,
prevented by coincident expression of PAI-1, TIMP-1 and
TIMP-2 [226, 233]. In contrast, when endothelial cells migrate,
they significantly up-regulate u-PA, u-PAR, and, to a lesser
extent, t-PA at the leading edge of migration [68, 69, 234–236].
Although PAI-1 is also increased, its expression at different
locations and times allows a net increase in fibrinolytic activity
[237–239]. A variety of cytokines and growth factors with angio-
genic activity modulate the expression of these proteinases.
VEGF-A and FGF2 (synergistically) induce expression of u-PA,
t-PA and u-PAR [71, 240, 241], whereas TNF-a and interleukin-1
up-regulate expression of MMP-1, MMP-3 and MMP-9. TGF-b1
down-regulates u-PA, and induces PAI-1, constituting thereby a
negative feedback for FGF2 and VEGF-A [71].
Although immunoneutralization or chemical inhibition of PAs
and MMPs reduce endothelial cell migration in vitro [68, 69],
surprisingly, mice deficient in u-PA and/or t-PA [236], PAI-1 [238,
242, 243], u-PAR [244, 245], Plg [246, 247] or alpha2-antiplasmin
(unpublished observations) develop normally without overt vas-
cular anomalies. This is also true for mice deficient in MMP-3,
MMP-7, MMP-9, MMP-11, MMP-12 or TIMP-1 [248–250].
Whether this relates to insufficient expression, redundancy or
compensation of these proteinases during vascular development,
or alternatively, to the fact that embryonic vessels have a poorly
developed basement matrix (rendering the need for proteinases
less significant) remains to be determined [1]. In the adult,
re-endothelialization alongside denuded vessels was not different
in mice deficient in t-PA, u-PA, u-PAR, PAI-1 and Plg [230, 238,
245, 246]. In contrast, hemangioblastoma formation after Poly-
oma middle-T retroviral infection was dependent on generation of
u-PA-mediated plasmin [251]. Also, neovascularization of the
ischemic myocardium appears to be dependent on u-PA-gener-
ated plasmin, as deduced from experimental myocardial infarct
studies in these transgenic mice (unpublished observations).
These data suggest that migration of endothelial cells alongside a
denuded vessel does not require u-PA-generated plasmin,
whereas invasion of endothelial cells through an anatomic barrier
of extracellular matrix requires plasmin proteolysis. Ongoing
studies in mice lacking fibrinolytic and/or matrix metalloprotein-
ases will reveal how significant these proteinases are for endothe-
lial cell migration in these and other models of neovascularization
(ischemic retinal neovascularization, skin wounding, etc.).
The plasminogen system may also be implicated in the inhibi-
tion of angiogenesis through generation of the angiogenesis
inhibitors angiostatin or the kringle 5 domain of plasminogen [62,
252]. Although such mechanisms may be important for tumor
dormancy in the adult [62, 253], it is unknown whether these
inhibitors affect embryonic vascular development or pathological
neovascularization except in cancer.
Endothelial cell-cell junction components
The endothelium forms the main barrier to passage of macro-
molecules and circulating cells from blood to tissues. Its perme-
ability is in large part determined by endothelial cell-cell junc-
tions. The transmembrane adhesive molecules of the cadherin
family are linked to an intracellular network of cytoplasmic
proteins and actin microfilaments [110]. They promote ho-
mophilic, calcium-dependent cell-to-cell recognition [254]. Al-
though the endothelium can express several members of the
cadherin family including the N-, P- and E-cadherin, only vascular
endothelial (VE)-cadherin concentrates at cell-cell junctions.
Mutagenesis studies of VE-cadherin demonstrate that the extra-
cellular domain is sufficient for the early steps of cell adhesion and
recognition, whereas the cytosolic tail is important for interaction
with the cytoskeleton in providing strength and cohesion to the
junction, and in limiting cell permeability. There is growing
evidence that cadherin-catenin complexes are also implicated in
the control of cell growth and differentiation. VE-cadherin may
stabilize blood vessels, as suggested by their poor expression in
aggressive endothelial tumors and by the inhibition of integrin
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synthesis by cadherins [255]. Tyrosine phosphorylation by
VEGF-A weakens these intercellular junctions, thereby increas-
ing the permeability, and allowing endothelial cell migration
(Dejana et al, personal communication). Other agonists including
thrombin, elastase or inflammatory cytokines can also modulate
VE-cadherin redistribution at junctions in parallel with an in-
crease in permeablity [256].
In the mouse embryo, VE-cadherin is ubiquitously expressed in
mesodermal cells from 7.5 days of gestation onwards, even before
the organization in blood islands, suggesting an important role for
it in endothelial cell function or during vessel assembly [257].
Deficiency of VE-cadherin did not abort endothelial cell differ-
entiation, but resulted in abnormal endothelial channel formation
in embryonic bodies in vitro. Endothelial cells remained dispersed,
and failed to organize vessel-like patterns [12]. Furthermore,
VE-cadherin deficient embryos die around 8.5 days of gestation,
presumably because of vascular defects (Dejana, personal com-
munication). Recent data futher indicate that immunoneutraliza-
tion of VE-cadherin in adult blood vessels results in increased
leakiness (Dejana et al, personal communication). Taken to-
gether, these data implicate an important role of VE-cadherin in
the formation and the maintenance of normal vessel integrity.
SMOOTH MUSCLE CELLS
Developmental regulation of smooth muscle cell assembly
In contrast to the vast literature on endothelial cell function
during blood vessel formation, relatively little is known about the
role of the periendothelial cells during this process [258]. Never-
theless, endothelial tubes are encapsidated by mural cells, such as
pericytes in the microvasculature, smooth muscle cells around
larger vessels, and cardiomyocytes surrounding the endocardium.
They play important roles not only during the initial sprouting and
remodeling of the emerging vascular bed, but in addition are
essential for the stabilization and maturation of the vasculature
via the production of specialized extracellular matrices (elastin
fibers). The biology of pericytes and smooth muscle cells has been
reviewed previously [26, 259–263]. Pericytes associate abluminally
with endothelial cells, protruding processes parallel to the long
axis of midcapillaries, or encircling the wall of pre- and postcap-
illary venules and arterioles. They produce several matrix compo-
nents (collagen I, III, IV, fibronectin, tenascin, laminin, glycos-
aminoglycans, osteolcalcin), and are “intramurally” embedded
within a basement membrane that is shared with the endothelium
[261]. They may, however, leave their basal membrane pockets to
become “extramural” perictyes during sprouting angiogenesis,
accompanying or even preceding the emigrating endothelial cells
[263]. Endothelial and pericyte cells make characteristic “peg-
and-socket” or tight junction contacts, and communicate with
each other possibly through gap junctions of the connexin family
[264]. The characteristics of the midcapillary pericytes gradually
change from those of a “transitional” phenotype to those of “true”
smooth muscle cells surrounding terminal arterioles, venules and
larger vessels. Although pericytes are more numerous, longer,
have more extensive processes, and make more endothelial
contacts around postcapillary venules than around venous or
arterial capillaries, the number of pericytes versus endothelial
cells in each vascular bed appears to be rather constant [259, 261,
262]. Pericytes have heterogeneous functions in different tissues,
suggesting tissue-specific regulation. For example, pericytes in the
brain have macrophage-like characteristics, express several pepti-
dases but are devoid of desmin, suggesting a role in control of the
blood brain barrier and peptide metabolism [265]. In contrast,
pericytes in the mesentery are reactive for desmin, suggesting
contractile properties [266]. The glomerular mesangial cells in the
kidney also have phagocytic properties, differing from the peri-
cytic Ito cells in the liver, or the parasinusoidal reticular cells in
the spleen or the bone marrow. Although tissues differ widely in
the number of pericytes or in their endothelial coverage (retina .
lung . skeletal muscle . cardiac muscle . adrenal gland, etc.),
the functional consequences of these differences during quiescent
or angiogenic conditions remain largely unknown [261].
Pericytes have been ascribed a variety of functions. They may
regulate capillary blood flow by contraction. Since the capillary
lumen (,10 mm) just allows the passage of red blood cells,
minimal changes of the capillary diameter may significantly im-
pact on capillary flow. Their expression of smooth muscle-like
contractile proteins (a-actin, tropomyosin, vimentin and myosin
isoforms), their close physical association and anchoring via
fibronectin-rich matrix to the endothelial cells, and their produc-
tion of, and responsiveness to, vasoactive molecules (endothelin,
nitric oxide) allow such vasomotor regulation [259]. Pericytes have
also been implicated in the maintenance of a selective permeabil-
ity barrier for plasma constituents, especially in the brain, where
they constitute a second front of phagocytes, engulfing materials
that cross the (damaged) endothelial cells [259, 267]. On venules,
pericytes are concentrated over and around endothelial cell
junctions as “umbrella cells,” and have been observed to control
extravasation of plasma macromolecules during histamine-in-
duced inflammation or angiogenesis [268, 269]. In other tissues
(the choroidal and skin capillaries), pericytes are aligned asym-
metrically along the capillary, as if to minimize any hindrance of
exchange of plasma nutrients [270]. Notably, pericytes are absent
from the fenestrated endothelium of the kidney and liver sinu-
soids.
Another property of pericytes is their plasticity in differentiat-
ing into smooth muscle cells, which could be relevant for the
transition of midcapillary pericytes to smooth muscle cells when
the vascular network expands and capillaries develop into arte-
rioles, for example, during hypoxia in the lung [271]. In addition,
pericytes may differentiate into adipocytes, osteoblasts and, in the
brain, into phagocytes [259]. Pericytes may also control endothe-
lial cell growth and differentiation (see below), and their respon-
siviness to hypoxia may be relevant in this context [115]. Intrigu-
ingly, pericytes are among the few cell types that thrive under
hypoxic conditions.
Pericytes/smooth muscle cells in different locations differ in
their embryonic origin. The mural cells of blood vessels proximal
to the heart are derived from cardiac neural crest cells (neuroec-
todermal origin), whereas those of vessels more distal to the heart
are derived from mesenchymal cells (mesodermal origin). Al-
though the mechanisms of pericyte and smooth muscle cell
recruitment and differentiation remain largely unknown, similar-
ities between endothelial and pericyte growth have been recog-
nized. One mechanism may involve their in situ differentiation
from mural precursors, similar to the “vasculogenic” differentia-
tion of angioblasts. Such differentiation of mesodermally derived
cells to smooth muscle a-actin expressing cells may occur in the
developing aorta, initially in the ventral vicinity and progressing
distantly from the endothelium [272]. Chimeric experiments have
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demonstrated that host endothelial cells invade bone primordia
grafted on the chorioallantoic membrane, whereas pericytes de-
velop from the graft mesenchyme [273].
Another mechanism of pericyte and smooth muscle recruitment
involves their (longitudinal) migration alongside a pre-existing
parent vessel to more distal sites, such as that which occurs during
hypoxic pulmonary hypertension [271]. Similar transitions of
midcapillary pericytes to smooth muscle cells occur during angio-
genesis, when midcapillaries develop into precapillaries and fi-
nally into arterioles [263]. A third mechanism involves “pericyte
sprouting.” Indeed, when endothelial cells (perpendicularly) em-
igrate from their pre-existing site during sprouting angiogenesis,
pericytes also “sprout” from their parental vessels. However, it is
still controversial whether pericytes follow and stabilize the endo-
thelial sprouts, or, rather, precede the emigrating endothelial cells
and promote angiogenic sprouting [26]. Evidence for the latter
hypothesis stems from observations that pericytes are the first
among endothelial and fibroblast cells to divide during sprouting
angiogenesis [274]. Moreover, desmin-positive pericytes were
frequently seen advancing endothelial sprouts for various dis-
tances, where they may serve as guiding structures for outgrowing
endothelial cells [266]. In contrast, support for the former hypoth-
esis is provided by findings that cocultivation of endothelial and
pericyte cells did not increase capillarization in fibrin gels [275],
and that intramural pericytes were only observed after endothelial
sprouts were formed (Benjamin and Keshet, personal communi-
cation, and [271]).
Endothelial cells are believed to recruit and organize mural
cells through intercellular communication, presumably via candi-
date signals such as PDGF-B [33, 276, 277], the angiopoietins [23,
24], tissue factor [31, 105, 278], and possibly FGF2. Once in
contact with endothelial cells, pericytes may inhibit endothelial
proliferation, as evidenced by the increased number of endothe-
lials in PDGF-B deficient microvessels lacking pericytes [33]. In
addition, they induce endothelial differentiation (including for
example the intracellular distribution of actin fibers), and prevent
tearing of endothelial cells by production of extracellular matrix.
TGF-b1, which only becomes activated when endothelial and
pericyte cells make close contact, appears to mediate these effects
[13, 70, 259]. Plasmin, generated from plasminogen by plasmino-
gen activators, which are produced by endothelial, pericyte or
epithelial cells, controls the activation of the latent TGF-b1.
Once the initial pericyte recruitment phase is over, the prenatal
blood vessels undergo another phase of development (matura-
tion), characterized by deposition of specialized extracellular
matrix components such as collagen, elastin and fibrillin. These
matrix components provide the developing arteries viscoelastic
properties (elastin and fibrillin-2) [279] and strength (collagen and
fibrillin-1) [209].
Postnatal regulation of smooth muscle cell assembly
Blood vessels retain the flexibility to adapt to changes in
hemodynamic stress or metabolic needs. Many of these adaptive
mechanisms follow a physical relationship (Laplace’s law), accord-
ing to which wall tension is proportional to the blood pressure and
to the radius of the vessel lumen, and inversely related to wall
thickness. Thus, when the vessel enlarges (for example after
balloon angioplasty or aneurysmal dilation), or when the blood
pressure increases (such as during hypertension), the wall thick-
ness increases (resulting from accumulation of smooth muscle
cells and extracellular matrix) in order to normalize the increased
wall stress. Conversely, when the lumen narrows due to the
development of atherosclerotic plaques, the vessel enlarges
(“compensatory adaptation”) [280]. In fact, failure of the athero-
sclerotic wall to compensatorily enlarge has been proposed as a
primary cause of lumen obstruction [281]. The importance of such
remodeling during restenosis is also highlighted by recent insights
that it is not the intimal thickening, but instead the total vessel
wall shrinkage that primarily determines lumen patency [282–
286].
Remodeling also allows the vessel to adapt to changes in the
need for increased blood flow, for example, during the growth of
collateral vessels during myocardial ischemia [58, 202]. Collateral
growth can result from increased capillary density due to sprout-
ing of preexisting (subendocardial) vessels, from recruitment via
vasodilatation of pre-existing arterioles [58], or from the enlarge-
ment and remodeling of pre-existing (epicardial) arterioles into
muscular arteries in situ [202]. The key importance of subepicar-
dial arterial remodeling is emphasized by the fact that the initial
vessel diameter may dramatically increase up to 20-fold and its
tissue mass up to 50-fold. The molecular mechanisms of this
remodeling have been recently reviewed [202]. As a result of the
increased blood flow in the non-ischemic myocardium, endothe-
lial cells express adhesion molecules on which monocytes adhere.
These activated macrophages infiltrate the vessel wall and, via
controlled release of PA and MMP proteinases, degrade the
elastic lamellae and the medial stroma. Macrophages produce
death ligands (TNF-a), which cause death of medial smooth
muscle cells and cardiomyocytes, thereby providing space to
accommodate outward vessel growth. Vessel enlargement is
achieved by an increased proliferation of smooth muscle and
fibroblast cells in the adventitia, media and intima (the latter
resulting in a thickened intima with a new internal elastic lamina),
presumably because the shear stress- and macrophage-activated
endothelial cells produce increased levels of PDGF-B, TGF-b1
and FGF2. As a result, the vessel enlarges and increases its total
mass.
Mural cells also contribute and respond to a variety of patho-
logical disorders. Increased numbers of pericytes have been
implicated in the lung during fetal pulmonary distress and adult
pulmonary hypertension, in atherosclerotic vessels, and in hyper-
tensive retinal vessels, where they may protect the endothelilal
cells against tearing [26, 259]. Since endothelial cells communicate
with pericytes, endothelial cell dysfunction may be a common
trigger. Excessive smooth muscle cell accumulation has also been
implicated in the pathogenesis of atherosclerosis [287] and arte-
rial restenosis [288]. In contrast, defects in pericyte or smooth
muscle cell function, whether congenital [289] or acquired during
proliferative diabetic microangiopathy (resulting in “pericyte drop
out”) leads to profound vessel weakness and aneurysmal dilation.
This may render the endothelial cells more responsive to angio-
genic signals, leading to neovascularization and hyperpermeability
with resultant blindness [26, 40, 54, 259]. Abnormal numbers of
pericytes around tumor neovessels have also been reported. Over
the last years, remarkable progress has been achieved in the
elucidation of the molecular mechanisms governing mural cell
(patho)biology. The insights deduced from gene targeting studies
will be reviewed in this section. Although some molecules (TGF-
b1, PDGF-B) exert a pleiotropic effect on both endothelial and
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periendothelial cells, their role is discussed here because of their
predominant periendothelial phenotype.
Tyrosine receptor kinase TIE2 and its angiopoietin ligands
Recently, two ligands for the TIE2 receptor, angiopoietin-1
(ANG1) and angiopoietin-2 (ANG2) were identified. ANG1
specifically induced tyrosine phosphorylation of TIE2 in endothe-
lial cells, but, surprisingly, failed to induce endothelial cell prolif-
eration, migration or tube formation in collagen gels [187]. In the
early embryo (9.0 days of gestation), ANG1 is most prominently
expressed in the myocardium. Subsequently (.13 days of gesta-
tion), ANG1 becomes more widely expressed throughout the
embryo, most often in the mesenchyme surrounding developing
vessels. Targeted disruption of the ANG1 gene resulted in
embryonic lethality around 11.0 to 12.5 days of gestation due to
abnormal cardiovascular development [23]. Vascular defects in-
cluded a less complex and immature vascular network, character-
ized by more dilated, and almost syncitial appearance of the
vessels, much less distinction in size between large and small
vessels, and fewer and straighter branches. Yet, there was no
difference in endothelial cell accumulation. These abnormal
vessels contrast with the highly branched vascular network with a
clear distinction in size between major vessels and smaller sprouts.
In addition, certain vessels, such as the intersomitic vessels,
appeared to regress beyond 11 days of gestation. Vascular defects
were more prominent in the yolk sac than within the embryo
proper. Together, these findings suggest that remodeling of the
initially homogeneous capillary network into both large and small
vessels is defective. Ultrastructural analysis revealed that, in
ANG1 deficient embryos, the endothelial cells were more
rounded and failed to make close contact with the subendothelial
extracellular matrix, and that there were fewer periendothelial
mesenchymal cells (most likely immature smooth muscle cell/
pericyte-like cells). In addition, the intervening space contained
fewer and scattered collagen-like fibers. These findings can be
explained by a failure in recruitment of periendothelial cells,
possibly because endothelial cells fail to transmit a recruiting
signal (PDGF-BB?) for mesenchymal cells in the absence of
ANG1. This results in impaired branching and vessel segmenta-
tion (intussuception), leading to more homogeneously dilated
vessels. Stabilization and maturation of the immature vessels is
compromized, resulting in increased fragility, rupture and “vascu-
lar” bleeding, and in other cases, in vessel regression.
ANG2 is a negative TIE2 ligand which blocks the action of
ANG1 in recruiting and sustaining periendothelial support cells
[24, 44]. In the presence of VEGF-A, ANG2 may promote
angiogenic sprouting by loosening the periendothelial cell support
and basement membrane encapsidation, whereas, in the absence
of the VEGF-A survival signal, it may induce vessel regression.
Not surprisingly, transgenic mice overexpressing ANG2 also die
during embryogenesis, with similar vascular defects as mice
lacking ANG1 or TIE2.
Interference with tie2 gene function was accomplished by
generation of transgenic mice with a dominant negative TIE2
mutant due to lysine-to-alanine mutation of codon 853 (tie2L853A)
in the intracellular domain, which abolished (auto)phosphoryla-
tion [290]. In addition, tie2 gene function was disrupted via
homologous recombination in embryonic stem cells (tie22/2) [21].
The tie2L853A and tie22/2 embryos displayed an enlarged pericar-
dial cavity and died in utero around 9.5 days of gestation. Up until
nine days of gestation, mutant embryos developed normally,
containing a normally patterned vasculature in both extra- and
intra-embryonic tissues. However, there were fewer large vessels
and a lack of vascular sprouts, for example, in the head mesen-
chyme. Overall, the immature blood vessels were dilated without
distinction between large and small vessels, and they were more
fragile and ruptured, inducing hemorrhaging in diverse cavities of
the body. In the yolk sac, there were 75% less endothelial cells in
the mutant blood islands. Thus, TIE2 does not appear to be
required for the initial appearance and differentiation of the
endothelial cell lineage, but is necessary for remodeling of the
primary capillary network into large and small vessels.
In a recent study, more insight in the role of TIE2 in cardio-
vascular morphogenesis has been obtained [25]. Heart develop-
ment in TIE2 deficient embryos was abnormal, as the endocard
was detached from its surrounding mesenchymal cells (the prim-
itive cardiomyoctes). Similar to the ANG1 deficient embryos,
impaired splitting of vessels in TIE2 deficient embryos resulted in
insufficient branching and the formation of singular, larger vessels
instead of a dense network of smaller networks. Ultrastructural
analysis indicated that capillary pillars during intussusceptive
growth contained fewer periendothelial cells, a more diffusely
arranged collagene network, and endothelial cells that were
unable to completely divide the lumen. At best, incomplete vessel
division in the mutant embryos occurred through a collapse of the
endothelial wall, connecting to the opposing endothelial wall. As
a result, the capillary pillars were more fragile and vascular loop
formation was defective, leading to bleeding and tissue ischemia.
In summary, TIE2 appears to play a crucial role in the differen-
tiation of mesenchymal cells to periendothelial cells during intus-
susceptive growth, whereas TIE1 appears to exert a more endo-
thelial cell-specific function.
Recently, an activating arginine-to-tryptophan mutation in the
kinase domain at position 849 of TIE2 receptor has been related
to the development of venous malformations, characterized by
significantly enlarged lumina of the vessels, with disproportionally
large numbers of endothelial versus smooth muscle cells [289]. In
fact, the smooth muscle cell layer was frequently underdeveloped
and disorganized, appeared patchy or was locally absent. Some-
what paradoxically, deficiency of the ANG1 ligand and superac-
tivation of the TIE2 receptor both result in impaired smooth
muscle cell recruitment, accumulation or differentiation. These
observations may be reconciled by postulating that ANG1 activa-
tion of the TIE2 receptor is functionally different from activation
by the R849W mutation, the precise molecular mechanisms of
which, however, need to be further unraveled.
Transforming growth factor-b1
Transforming growth factor-b1 (TGF-b1) is a multifunctional
cytokine capable of affecting blood vessel formation [52, 291–
293]. It can bind to several cellular receptors on endothelial cells,
of which the receptor serine/threonine kinases type I and II have
been identified as signal transducing TGF-b1 receptors. In addi-
tion, TGF-b1 interacts with other molecules such as betaglycan
and endoglin, and a combination of interactions between these
TGF-b binding molecules may modulate its biological role.
TGF-b1 inhibits macrovascular endothelial cell proliferation,
induces apoptotic endothelial cell death, impairs endothelial cell
migration, and reduces their proteolytic activity in vitro [52, 70].
However, TGF-b1 exerts pleiotropic and bimodal effects on
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endothelial cells in vitro, which largely depend on its concentra-
tion, on the type and the density of endothelial cells, on the nature
of extracellular matrix components, and on the interaction with
other growth factors such as FGF2 and VEGF-A [52, 294]. In fact,
TGF-b1 has also been shown to promote proliferation of angio-
genic endothelial cells, to induce formation of capillary-like tubes,
and to increase expression of endothelial PECAM, fibronectin
and tight cell junctions in vitro [52, 295]. The latter properties may
explain why TGF-b1 is angiogenic in vivo. However, TGF-b1 may
induce blood vessel formation in vivo indirectly via affecting
inflammatory or connective tissue cells which in turn can produce
angiogenic molecules such as VEGF-A, PDGF, FGF2, etc. [52,
66, 123, 125, 296].
Besides a possible direct endothelial cell effect, TGF-b1 may
control blood vessel formation via an effect on peri-endothelial
mesenchymal cells by inhibiting their growth and migration, by
promoting their differentiation (for example, a-actin production),
and by inducing their production of extracellular matrix [297–
299]. However, the role of TGF-b1 on smooth muscle cell
function remains controversial, as TGF-b1 gene transfer to the
arterial wall or prolonged administration of TGF-b1 protein
stimulates intimal thickening [300–302], whereas neutralizing
anti-TGF-b1 antibodies reduces this process [303]. The effect of
TGF-b1 to increase extracellular matrix production appears to be
the most consistent mechanism of action. The apparently contra-
dictory roles of TGF-b1 may be attributable, at least in part, to the
bimodal effect of TGF-b1 on smooth muscle cell proliferation via
the complex control of an autocrine PDGF-AA loop [304, 305].
Alternatively, the cellular response to TGF-b1 may depend on the
cell type (embryonic vs. adult smooth muscle cell phenotype,
pericytes vs. smooth muscle cells, etc.), or depend on the contex-
tual presence of other signaling molecules [123]. Endothelial and
smooth muscle cells secrete TGF-b1 in a biologically inactive
form that can be activated by plasmin, but only when both cell
types make close contact with each other [70]. TGFb-1 has been
implicated in pathological vessel development, restenosis, hyper-
tensive remodeling and atherosclerosis [287].
Targeted inactivation of the TGF-b1 gene resulted in embry-
onic lethality in approximately 50% of homozygous TGF-b1
deficient embryos around 9.5 days post-coitum [13]. Analysis of
TGF-b1 deficient embryos revealed vascular defects in the yolk
sac ranging from delay in vasculogenesis and development of
small, disorganized and fragile vessels to regional absence of yolk
sac vessel formation. These vascular defects in the yolk sac
appeared to compromise vitello-embryonic circulation and to
induce wasting of the embryos, which revealed no specific defects
or abnormalities per se. In some embryos, the allantois failed to
fuse with the chorion, compromizing the chorio-allantoic placen-
tal circulation. Deficiency of TGF-b1 did not appear to affect
early differentiation of endothelial cells, nor to reduce endothelial
cell proliferation. However, there were frequently no contacts in
the yolk sac between the endothelial cell layers and the apposed
visceral endoderm and mesothelial cells, respectively, suggesting
that these contacts had either not formed or were disrupted. As a
result, the immature vitelline vessels were fragile, lacking struc-
tural support, and ruptured with leakage of blood in the yolk sac.
Deficiency of the TGF-b receptor type II similarly resulted in
embryonic lethality due to defects in hematopoiesis and vasculo-
genesis [306].
These results suggest that TGF-b1 is essential for the early
steps of blood vessel formation (vasculogenesis). It is unclear
whether this is due to abnormal expression of cell adhesion
molecules (which could explain the abnormal capillary plexus
formation as in the VE-cadherin deficient embryonic bodies [12]),
or of VEGF-A (which could explain the defective lumen forma-
tion, the disorganized vessel assembly and the reduced sprouting
as in the VEGF-A deficient embryos [8]). Other unresolved
questions are whether disorganization of the primary capillary
plexus results from unrestricted plasmin proteolysis (as occurs in
cystic hemangiomas [251]), or whether the impaired chorio-
allantoic fusion relates to insufficient expression of adhesion
molecules (as occurs in the VCAM-1 deficient or in the a4
integrin-deficient embryos [28, 30]). Impaired terminal endothe-
lial differentiation may also play a role, as suggested by the
reduced number of endothelial cells expressing FLK1. In addition,
TGF-b1 appears to be essential for vascular integrity and matu-
ration of the vascular bed. Although the precise cellular mecha-
nism was not elucidated, it is possible that deficiency of TGF-b1
impaired the differentiation of mesenchymal cells to pericytes, or
reduced their production of extracellular matrix. Matrix compo-
nents (such as fibronectin, which is induced by TGF-b1) signifi-
cantly determine embryonic vascular integrity [10]. Since TGF-b1
down-regulates angiopoietin-1 (ANG1) [139], it remains to be
solved whether ANG1 levels are increased in the mutant embryos,
and how this can be reconciled with the increased capillary
fragility. Patients with hereditary hemorrhagic teleangiectasia
(Rendu-Osler-Weber syndrome) have been shown to carry muta-
tions in two TGF-b1 binding proteins, endoglin and activin
receptor-like kinase [307], further underscoring the role of
TGF-b1 in development and maturation of the vascular bed.
Platelet-derived growth factor and its receptor
The platetelet-derived growth factor (PDGF) family includes
three dimeric ligands, PDGF-AA, PDGF-AB and PDGF-BB,
encoded by two different genes [52, 191, 308, 309]. As for
TGF-b1, PDGFs have pleiotropic actions on both endothelial and
mural cells, but since the evidence for an effect on pericytes and
smooth muscle cells is more convincing, its role is discussed in this
section. The PDGF receptor type-alpha (PDGFR-a) binds the A-
or the B-chain of the PDGF dimers with high affinities, whereas
the PDGF receptor type-b (PDGFR-b) only binds the B-chain.
PDGFs are abundantly detected in the a-granules of platelets, but
also in smooth muscle cells, leukocytes and endothelial cells.
PDGF-BB is angiogenic in vivo [310–312]. However, it is not clear
whether PDGF-BB acts directly on endothelial cells, or elicits
these effects by recruitment of inflammatory cells and mesenchy-
mal cells, which produce angiogenic factors such as VEGF-A,
TGF-b1 or FGF2 [52, 66, 123, 125]. In vivo, angiogenic microcap-
illary endothelial cells coexpress PDGF-BB and PDGFR-b [277],
whereas regenerating macrovascular endothelial cells coexpress
PDGF-A and PDGFR-a [313], suggesting autocrine endothelial
growth control by PDGF. In vitro, PDGF-BB induces prolifera-
tion and tube formation via interaction with PDGF-b receptors
but only in developing angiogenic endothelial cell cords [52, 314].
In contrast, macrovascular endothelial cells maintain expression
of PDGF-BB, but lack expression of PDGFR-b and fail to
proliferate in response to PDGF-BB.
Apart from an effect on endothelial cells, endothelial
PDGF-BB appears to affect blood vessel formation by inducing
migration and proliferation of PDGFR-b expressing pericytes in a
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paracrine loop. Smooth muscle PDGF-AA may stimulate growth
of smooth muscle cells in an autocrine loop [52, 191, 259, 277, 308,
313, 315]. Notably, PDGF-BB appears to induce a migratory
rather than a contractile differentiation, as evidenced by the
reduced levels of a-actin levels in PDGF-stimulated cells [316].
This suggests that other factors (TGF-b1, tissue factor?) are
present to induce a contractile differentiation state, once mural
cells have been recruited to the endothelium. Application of the
PDGF-B protein [317], or enhancement of PDGF-B expression in
the vessel wall [318] induces neonitima formation, whereas inhi-
bition of PDGF activity [319] or of PDGFR-b production in vivo
[320] suppresses arterial remodeling and initimal thickening.
Targeted disruption of the PDGF-B gene resulted in defective
development of the vascular smooth muscle cell lineage [32]. This
was particularly striking during kidney glomerular development
beyond 17 days of gestation, revealing abnormal development of
the smooth muscle cells around the glomerular vessels. In contrast
to the detailed capillary network of a normal glomerular tuft, the
capillary tuft of the mutant glomeruli was missing, and instead, the
Bowman’s capsular space contained one or several capillary
aneurysm-like structures filled with blood. Ultrastructurally, these
aneurysm-like structures were delineated by basement mem-
branes, with podocytes on their outer surface and endothelial cells
lining their inside. However, mesangial cells (which are pericyte-
like cells of the kidney vasculature) could not be identified in
mutant glomeruli. Thus, it is possible that PDGF-BB, initially
expressed by the differentiating glomerular epithelium, recruits
mesangial progenitor cells and subsequently, when PDGF-BB and
PDGF-b receptor are expressed by mesangial cells, stimulates
proliferation of mesangial cells in an autocine loop [321]. Lack of
pericytes throughout the entire microvascular bed, due to im-
paired recruitment (and proliferation) of PDGFR-b positive
vascular wall progenitors, also explains why PDGF-B-deficient
capillaries were tortuous, variable in diameter and aneurysmal,
ultimately contributing to perinatal death owing to generalized
hemorrhaging [33]. Interestingly, naked endothelial tubes at sites
of pericyte loss contained increased numbers of endothelial cells,
suggesting inhibitory control by pericytes. It is currently unclear
which signals (tissue factor or ANG1?) stimulate induction of
these vascular wall progenitors.
Loss of PDGF-B gene function also caused other defects of the
smooth muscle lineage development [32]. Indeed, the large arter-
ies of the mutant embryos were markedly dilated. However, since
the number of smooth muscle cell layers appeared normal,
deficiency of PDGF-B resulted in dysfunction rather than hypo-
plasia or hypotrophy of the smooth muscle cells, possibly related
to the vasoconstrictor properties of PDGF [308]. Similar defects
in kidney development and hematopoiesis were observed in mice
lacking the PDGFR-b [322], suggesting that these processes result
from signaling of PDGF-BB through the PDGFR-b. Analysis of
wild-type 7 PDGFR-b-deficient chimeric mice reveals the ab-
sence of differentiated smooth muscle cells in the aortic wall,
suggesting that the PDGFR-b plays an essential cell-autonomous
role in smooth muscle cell development (Bowen-Pope et al,
personal communication). Thus, PDGF-BB is not critical for
endothelial tube formation, but appears to play a central role in
the structural integrity of the endothelial tubes via an effect on
recruitment of pericytes (and possibly other functions). PDGF-A
may also be crucial for the development of the heart and blood
vessels, as Patch mice (lacking PDGFR-a) contain fewer smooth
muscle cells around their normal endothelial tubes, as well as a
thinned myocardium [323].
Fibroblast growth factor
Collateral vessels are a heterogeneous group consisting of
mainly two classes: those of capillary size (,10 mm) or slightly
larger, devoid of a muscular coat and predominantly located in
the subendocardium, and those that are much larger, muscular-
ized and located epicardially [47, 201, 202]. Therapeutically
administered FGF2 improves myocardial function in ischemic
hearts and reduces the infarct size [57, 203]. Its beneficial effect is
only partially due to increased FGF2-mediated capillarization.
Indeed, FGF2, because it is a general mitogen, may also be
involved in the growth of smooth muscle cells during arterial
remodeling of the epicardial collaterals [202]. Another possible
mode of action for FGF2 (as also for VEGF-A) is an increased
recruitment of pre-existing arterioles via nitric oxide-dependent
vasodilation [58]. In addition, it is conceivable that FGF2 (which
is constitutively expressed in the normal heart) may be a trophic
factor with a surival value for terminally differentiated cells such
as cardiac myocytes. Indeed, in contrast to VEGF-A, which is
rapidly (within minutes) induced by acute hypoxia, FGF2 expres-
sion is only increased during chronic ischemia through activation
of macrophages [202].
Extracellular matrix
The stromal matrix in blood vessels contains collagens I and III,
elastin and fibrillin fibers, which each have distinct functions.
Elastin is organized into polymers that form concentric rings of
elastic lamellae around the arterial lumen [279]. Each lamella
alternates with a ring of smooth muscle cells, forming a lamellar
unit, the number of which is proportional to the thickness of the
vessel wall. Elastin is easily stretched, doubles its length and
springs back to its original dimensions. It is responsible for the
elastic recoil of large arteries that allows them to store energy
produced by cardiac contraction and to release it during cardiac
relaxation. In contrast, fibrillar collagens have a tensile strength
over 20 times greater than that of elastin and is very difficult to
stretch; it cannot extend beyond a small proportion of its original
length before structural damage occurs. In fact, aortic collagen is
coiled up in such a way that, initially, the (normal) load on the
aorta is borne by elastin and only at higher (supraphysiological)
loads, collagen fibers become progressively recruited as load
bearing elements, acting as an immensely strong but almost
indistensible ‘safety net’ [209, 324]. Although it was originally
thought that elastin was only synthesized during the prenatal stage
of embryogenesis [279], recent studies provide evidence for de
novo elastin synthesis in injured or aneurysmal blood vessels [325].
Whereas collagen III is quantitatively more important during fetal
development, collagen I is more abundant in the adult. Increased
collagen deposition is a common finding during fibrotic healing of
the myocardium and of peripheral vessels during mechanical,
ischemic, or chemical injury, and may prevent aneurysm rupture
in conditions of elastin desintegration. There are fewer elastic
lamellae in the abdominal aorta, explaining in part why (athero-
sclerotic) aneurysms are more frequent and severe in the abdom-
inal aorta [324–326]. Disruption of elastin or fibrillin results in
aneurysmal dilatation, but additional loss of collagen fibers is
required to induce rupture of the vessel wall [324–327].
Disruption of collagen I in mice results in abnormal fragility
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and rupture of large blood vessels with fatal bleeding at 12 days of
gestation [328]. Mutations in collagen III in humans [329] or in
mice [330] result in aortic or cerebral aneurysm formation and
fatal rupture, and a much shorter life span (Ehlers Danlos
complex type IV or other familial disorders). Collagen III is an
important regulator of type I collagenogenesis, as collagen I fibers
are wider but significantly underrepresented in the adventitia of
collagen III-deficient arteries. In contrast, deficiency of fibrillar
collagen V, which links the stromal with the basement membrane
collagens and regulates fibril diameter, induces spinal deformities
without vascular anomalies [331]. Hemizygous mutations of the
elastin gene in humans have been correlated with obstructive
supravalvular aortic stenosis due to an increased number of elastic
lamellae [332, 333]. Mice homozygously deficient of elastin totally
lack elastic lamellae and die perinatally due to obstructive arteri-
opathy resulting from excessive subendothelial smooth muscle cell
accumulation (M. Keating et al, personal communication).
Whether these findings implicate a role for elastin in controlling
smooth muscle cell proliferation (similar to collagen [334]),
remains to be determined.
Microfibrils, including fibrillin and fibronectin, play a role in
connecting the underlying collagen and elastin fibers with the
basement membrane [332, 333]. Fibrillin-1 provides tensile
strength and contributes load-bearing properties to the aortic
adventitia, whereas fibrillin-2 regulates the onset of the formation
of elastic fibers by guiding tropoelastin deposition during embry-
ogenesis and early postnatal life [335]. An extensive network of
microfibrils links the endothelium in blood or lymphatic capillar-
ies to their surrounding stroma, providing capillary integrity [209].
Patients with Marfan syndrome who express large amounts of a
dominant negative fibrillin-1 die because of aneurysmal dilatation
of the ascending thoracic aorta and aortic dissection, whereas
patients with low expression levels suffer a milder Marfanoid
phenotype [336]. Targeted mutagenesis of the fibrillin-1 gene in
mice resulted in low expression levels of a dominant negative
fibrillin-1, resulting in a severe vascular Marfan phenotype (peri-
natal aneurysmal aortic dilation and rupture) in homozygous but
not in heterozygous mutant mice [337]. Since elastin fibers
assembled in the absence of normal fibrillin-1, the latter is not
essential for this process. However, the significant weakening of
the adventitia suggests that fibrillin-1 plays an important role in
the proper organization of the primarily collagenous connective
tissue in the adventitia. Secondary to the loss of tensile stress in
the weakened adventitia (which bears the bulk of hemodynamic
stress), the elastin fibers in the media become overstretched and
fracture, further contributing to vessel wall fragility. Patients with
mutations of fibrillin-2 or elastin do not suffer aortic dilation,
confirming the important role of collagen fibers in the adventitia
in providing structural strength and integrity to the vessel wall
[333, 338].
Extracellular matrix proteinases I: The coagulation system
Initiation of the plasma coagulation system is triggered by tissue
factor (TF), which functions as a cellular receptor and cofactor for
activation of the serine proteinase factor VII (FVII) to factor
VIIa (FVIIa) [339–342]. Activation of factor VII can be per-
formed by FVIIa (autoactivation), factor IX, factor X, factor XII
or hepsin [340]. The TF z FVIIa complex activates factor X either
directly, or indirectly via activation of factor IX, resulting in the
activation of prothrombin to thrombin and in the conversion of
fibrinogen to fibrin. Factor X can, however, also become activated
by FVIIa bound to an as yet undefined cellular binding site, as
well as by other processes involving Mac-1, glycoprotein c and
tumor procoagulant. Because of an efficient FXa-dependent
feedback inhibition of TF z FVIIa by the Kunitz domain-type
inhibitor tissue factor pathway inhibitor (TFPI), which is synthe-
tized primarily by and bound to the endothelium of microvessels,
coagulation is initiated but rapidly shut off. Therefore, sustained
progression of the coagulation has been proposed to depend on a
positive feedback stimulation by thrombin and factor Xa, which
activate factor XI, factor VIII and factor V (the latter two serving
as membrane-bound receptors/cofactors for the proteolytic en-
zymes factor IXa and factor Xa, respectively) [343]. Apart from
antithrombin III, anticoagulation results from interaction of
thrombin with thrombomodulin, thereby activating protein C
which, together with protein S, inactivates factor Va and factor
VIIIa in a negative feedback loop [344]. Evidence has been
provided that the coagulation system may be involved in other
functions beyond fibrin-dependent hemostasis including cellular
migration and proliferation, immune response, metastasis and
brain function [106, 339–341, 345]. The following evidence sug-
gests that tissue factor participates in processes beyond initiation
of fibrin formation: (i) it is a member of the immunoglobulin
superfamily and expressed as an immediate early gene during
inflammation and immune challenge [339, 340]; (ii) its intracellu-
lar domain mediates signaling during metastasis, cellular activa-
tion or growth factor production [340]; (iii) it may participate in
tumor neovascularization, possibly via an effect on VEGF expres-
sion [107, 108, 346], and (iv) it is expressed in a variety of
embryonic tissues including the visceral endoderm cells in the yolk
(which surround the endothelium), and at later stages, in the
smooth muscle cells of larger blood vessels [347, 348]. Its precise
role and relevance in these processes in vivo remains, however,
largely unknown.
Targeted inactivation of the tissue factor (TF) gene resulted in
increased fragility of endothelial cell-lined channels in the yolk sac
in 80 to 100% of the mutant embryos [31, 349–351]. At a time
when the blood pressure increased during embryogenesis (day 9
of gestation), the immature TF deficient blood vessels ruptured,
formed micro-aneurysms and ‘blood lakes,’ and failed to sustain
proper circulation between the yolk sac and embryo [31]. Since
these are essential for transferring maternally derived nutrients
from the yolk sac to the rapidly growing embryo, the embryo
became wasted and died due to generalized necrosis. Only in
advanced stages of deterioration did the immature blood vessels
become leaky, which resulted in bleeding into the extracoelomic
cavity. Similar observations were made when TF deficient em-
bryos were cultured in vitro, suggesting that the observed vascular
defects in the yolk sac were not merely due to a possible defect in
feto-maternal exchange [31].
Visceral endoderm cell functions appeared normal, suggesting
that they were not responsible for the vascular defects. In contrast,
defective development and/or recruitment of periendothelial mes-
enchymal cells (primitive smooth muscle cell or pericytes) ap-
peared to be a likely reason for the vascular defects. These cells
surround the endothelium in yolk sac vessels, form a primitive
“muscular” wall and provide structural support by their close
physical association and their increasing production of extracel-
lular matrix proteins. Microscopic and ultrastructural analysis
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revealed that deficiency of tissue factor resulted in a 75% reduc-
tion of the number of mesenchymal cells, and a diminished
amount of extracellular matrix [31]. Immunocytochemical analysis
further revealed a reduced level of smooth muscle a-actin staining
in these cells, suggesting impaired differentiation and/or accumu-
lation. Because these primitive smooth muscle cells provide
structural support for the endothelium, the vessels in the mutant
embryos are too fragile and break open. Although our analysis did
not reveal overt endothelial defects, we cannot exclude any subtle
abnormalities since their growth, differentiation and survival are
largely determined by the presence of pericytes [259]. An unre-
solved issue is whether the absence of TF reduces VEGF expres-
sion in these embryos [104], which could affect endothelial [56] as
well as periendothelial [113–115] cell function.
In contrast to the severe TF deficient embryonic lethality,
deficiency of FVII did not compromize embryonic development
and only caused fatal bleeding after birth [352]. Differences in
genetic background did not appear to explain the different
phenotypes, since deficiency of TF, when generated in a similar
mixed C57Bl/6J 3 129/SvJ background as FVII, still caused 85%
embryonic lethality [351]. Transfer of maternal FVII did not
appear to rescue the FVII deficient embryos as it was minimally
detectable, even at supraphysiological maternal FVII plasma
levels [352]. In fact, maternal FVII was adsorbed onto and
detectable inside the visceral endoderm cells of the yolk sac and
the syncytiotrophoblast cells in the placenta. These cells form the
feto-maternal barrier and are involved in degradation of most
maternal serum proteins to nutritive amino acids. In addition, it
should be emphasized that FVII mRNA levels in the yolk sac at
9.5 days of gestation were minimal, and that FVII plasma levels in
wild-type embryos at 11.5 days of gestation were only ;0.2% of
those present in adult mice.
To investigate the mechanism of action of embryonic TF, its
presumed hemostatic role in fibrin formation during embryogen-
esis was studied [352]. Surprisingly, fibrin deposits in the visceral
yolk sac were not observed in our ultrastructural and immunocy-
tochemical analysis of wild-type embryos, as would be expected if
TF deficient embryos would die secondarily to a fibrin-dependent
hemostatic defect. Furthermore, intracardial injection of a
TF z FVIIa inhibitor (rNAPc2, which blocks TF z FVIIa in a factor
Xa-dependent manner, but does not inhibit factor Xa activity by
itself) in such early stage embryos failed to induce bleeding at
levels that consistently induced bleeding in postnatal mice by
impairment of platelet/fibrin clot formation. In addition, intra-
cardial injection of thrombin failed to induce fibrin deposits in
these early embryos. These findings (as well as the minimal fibrin
deposits in 9.5-day-old TFPI deficient and thrombomodulin defi-
cient embryos; see below) raise some critical questions about the
presumed role of TF and FVII during early embryonic hemosta-
sis. We cannot exclude that minimal transfer of maternal FVII
(undetectable by the present techniques) rescues FVII deficient
embryos. However, such minimal FVII transfer did not appear to
induce detectable fibrin formation, which raises the possibility
that early embryonic hemostasis may be less dependent on fibrin
formation than anticipated. In fact, generation of the coagulation
factors Xa or thrombin (or others) may be also (or even more)
important for vascular development, as they affect proliferation
and migration of vascular cells directly [106, 345, 353], or indi-
rectly via release of PDGF [308]. The abnormal embryonic
development in embryos lacking the thrombin receptor (PAR-1)
[354] or factor V [355], in contrast to the normal development of
fibrinogen deficient embryos [356], may underscore the important
role of thrombin during embryonic hemostasis. Factor Xa activity
or thrombin generation would not be blocked by rNAPc2 if factor
Xa was present at the time of rNAPc2 administration, or if factor
Xa generation occurred via one of the known TF z FVIIa inde-
pendent mechanisms. TF may also be directly mitogenic or
chemotactic for smooth muscle cells via intracellular signaling
[105]. Intracellular TF-signaling has also been implicated in the
production of growth factors such as VEGF (DeProst et al,
personal communication), which could increase the permeability
of embryonic vessels (and thereby the availability of other plasma
molecules to the periendothelial space), or modulate the function
of smooth muscle cells (see above). An intriguing but unsolved
question is whether TF would act independently of FVII, as has
been suggested during cellular migration and adhesion (Mueller
et al, personal communication) or, perhaps via interaction with
another ligand (apolipoprotein B100 [357] and plasminogen [358]
are possible ligands). Whatever the molecular mechanism, TF
appears to be play a central role in vessel wall integrity. Our initial
analysis in completely TF deficient embryos (generated by tet-
raploid aggregation) suggests that TF expressed by the periendo-
thelial pericytes themselves and not by the adjacent visceral
endoderm cells may be important.
More than half (60%) of the embryos expressing a mutant TFPI
without the first Kunitz domain (which impairs interaction with
factor VIIa but not with factor Xa) die around a similar time as
the TF deficient embryos because of impaired vascular integrity
and bleeding, and with a remarkable phenocopy of the TF-
deficient vascular defects [359]. The remainder of the TFPI
deficient embryos develop until birth but suffer fatal consumptive
coagulopathy around birth. However, in contrast to the marked
intravascular thrombosis in TFPI deficient neonates, surprisingly
little fibrin was observed in 9.5-day-old TFPI deficient embryos. It
is at present undetermined whether the bleeding in early TFPI
deficient embryos was due to exhausted fibrin formation, or due to
abnormal vascular integrity, such as that which is caused by
depletion of morphogenic coagulation factors (factor Xa or
thrombin). In addition, alternative roles of TFPI might be con-
sidered, such as inhibition of trypsin or yet unknown functions.
Thrombin has been implicated in processes beyond hemostasis.
Indeed, it is mitogenic for fibroblasts and vascular smooth muscle
cells, chemotactic for monocytes and activates endothelial cells
[106]. Many of the cell signaling activities of thrombin appear to
be mediated by the currently identified thrombin receptors,
PAR-1 and PAR-3 [360]. Expression studies have suggested that
the PAR-1 participates in inflammatory, proliferative or repara-
tive responses such as restenosis, atherosclerosis, neovasculariza-
tion and tumorigenesis [106]. In addition, in situ analysis indicated
that this receptor is expressed during early embryogenesis in the
developing heart and blood vessels, in the brain and in several
epithelial tissues [347]. Targeting of PAR-1 resulted in a block of
embryonic development in approximately 50% of the homozygous
deficient embryos around a similar developmental stage as in TF
deficient embryos, presumably resulting from abnormal yolk sac
vascular development [354, 361]. Although the cellular defect was
not characterized in detail, vitelline vessels appeared to be
abnormal, resulting in increased fragility of blood vessels with
secondary rupture, blood leakage and pallor of the embryo.
Similarly enlarged pericardial cavities in PAR-1 deficient embryos
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suggested compromized vitello-embryonic blood circulation.
Other coagulation factors might also appear to be involved in
morphogenic processes during early embryogenesis, possibly in
blood vessel formation. Deficiency of factor V resulted in embry-
onic lethality in approximately half of the homozygously deficient
embryos, possibly due to vascular defects in the yolk sac [355].
Thrombomodulin deficient embryos also die during early gesta-
tion but the precise cause of lethality remains unclear [362].
Notably, fibrin deposits were not observed. Generation of mice
with targeted mutations of thrombomodulin may help to resolve
its mechanism of action. Initial analysis (in collaboration with E.
Conway) indicates that mice expressing a mutant thrombomodu-
lin without a cytosolic tail or mice heterozygous for another
mutant thrombomodulin without a lectin-like domain develop
normally.
Taken together, findings to date show that hemostasis in the
early embryo (approximately 9 days of gestation) may be less
dependent on fibrin formation and platelet function (thrombocy-
topenic embryos develop normally and bleed only postnatally
[363]) than anticipated. Later during embryogenesis, probably
around midgestation when the embryo produces larger quantities
or a more complete set of coagulation factors, hemostasis appears
to become typically dependent on fibrin formation as during
adulthood. Indeed, embryos expressing a mutant factor V Leiden
(D. Ginsburg, personal communication), TFPI or lacking protein
C (in collaboration with L. Jalbert, E. Rosen and F. Castellino,
Notre Dame, USA) progressively develop fibrin deposits before
birth (beyond 12 days of gestation in mutant TFPI embryos). It is
therefore not surprising that postnatal bleeding occurs in (the
surviving fraction of) mice deficient of factor V [355], factor VII
[352], factor VIII [364], factor IX and fibrinogen [356] due to
defective clot formation following trauma of normally developed
blood vessels (see below).
Proteinases II: Plasminogen and matrix metalloproteinases
Cell migration requires proteolysis of the extracellular matrix.
Somewhat surprisingly, proteinases of the plasminogen activator
(PA) or of the matrix metalloproteinase (MMP) system are not
required for mural cell migration during embryogenesis. In con-
trast, gene targeting studies have revealed that they play a
significant role during pathological smooth muscle cell migration,
as well as in vessel wall integrity.
Arterial stenosis. Vascular interventions for the treatment of
atherothrombosis induce “restenosis” of the vessel within three to
six months in 30 to 50% of treated patients [288, 365]. The risk
and costs associated with reinterventions represent a significant
medical problem, mandating a better understanding at the mo-
lecular level of this process. Arterial stenosis may result from
remodeling of the vessel wall (such as occurs predominantly after
balloon angioplasty) and/or from accumulation of cells and extra-
cellular matrix in the intimal layer (occurring predominantly after
intraluminal stent application) [286, 366]. Several candidate mol-
ecules have been identified based on correlative expression stud-
ies, but their in vivo role has frequently remained obscure.
Somewhat surprisingly, the genetic basis of the susceptibility to
arterial stenosis has only been studied in a limited fashion.
Although the availability of transgenic mice offers a novel oppor-
tunity to study the role of candidate genes in this process, the lack
of feasible and appropriate mouse models of arterial stenosis has
limited such progress. We and others have developed models of
arterial injury in the mouse and, although they may not represent
an ideal model of human restenosis, they permit the study of the
biological role and mechanism of the candidate genes, and we
have thus begun to assemble a molecular analysis of the underly-
ing mechanisms.
Proteinases participate in the proliferation and migration of
smooth muscle cells, and in the matrix remodeling during arterial
wound healing [27, 232, 367]. Two proteinase systems have been
implicated, the plasminogen (or fibrinolytic) system and the
metalloproteinase system, which in concert can degrade most
extracellular matrix proteins. PAI-1 is expressed by uninjured
vascular smooth muscle cells [226, 233]. u-PA, t-PA and (to a
lesser degree) PAI-1 activity in the vessel wall is significantly
increased after injury, coincident with the time of smooth muscle
cell proliferation and migration [234, 236–238, 368]. Of the
MMPs, only MMP-2 appears to be expressed in the quiescent
smooth muscle cells, whereas expression of MMP-3, MMP-7,
MMP-9, MMP-12 and MMP-13 is induced in injured, trans-
planted or atherosclerotic arteries ([369–374] and unpublished
observations).
Two experimental models of arterial injury were used, one
based on the application of an electric current [375] and the other
on an intraluminal guidewire [236, 238] to examine the molecular
mechanisms of neointima formation in mice deficient in fibrino-
lytic system components. The electric current injury model differs
from mechanical injury models in that it induces a more severe
injury across the vessel wall and results in necrosis of all smooth
muscle cells. This necessitates wound healing to initiate from the
adjacent uninjured borders and then to progress into the central
necrotic region, allowing the migration of smooth muscle cells to
be quantitated. Microscopic and morphometric analysis revealed
that the rate and degree of neointima formation and the neoin-
timal cell accumulation after injury were similar in the wild-type,
t-PA deficient and u-PAR deficient arteries [236, 245]. However,
neointima formation in PAI-1 deficient arteries occurred earlier
after injury [238]. In contrast, both the degree and the rate of
arterial neointima formation in u-PA deficient, Plg deficient and
combined t-PA:u-PA deficient arteries were significantly reduced
until four to six weeks after injury [236, 246]. Infiltration of the
media by leukocytes was also significantly reduced in Plg deficient
mice [246]. Similar genotypic differences were observed after
mechanical injury [236, 238], which more closely mimics the
balloon-angioplasty injury in patients.
Evaluation of the mechanisms responsible for these genotype-
specific differences in neointima formation revealed that prolif-
eration of medial and neointimal smooth muscle cells was only
marginally different between the genotypes [236, 238, 245, 246].
Impaired migration of smooth muscle cells is a likely cause of
reduced neointima formation in mice lacking u-PA-mediated
plasmin proteolysis, since smooth muscle cells migrate over a
shorter distance from the uninjured border into the central
injured region in Plg deficient than in wild-type arteries [236, 246].
In addition, migration of u-PA deficient smooth muscle cells, but
not of t-PA deficient or u-PAR deficient smooth muscle cells,
cultured in the presence of serum, was impaired after scrape
wounding [236]. Notably, when smooth muscle cells were cultured
without serum, u-PA was essential for migration induced by
FGF2, wheres t-PA was required for migration induced by
PDGF-BB [376]. The requirement of u-PA is consistent with the
more than 100-fold increased expression levels of u-PA mRNA,
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immunoreactivity and zymographic activity by migrating smooth
muscle and inflammatory cells. Besides the genotypic effects on
the media and intima, adventitial remodeling with infiltration of
leukocytes and myofibroblasts was also severely impaired,
whereas intravascular thrombosis (albeit transient) was more
frequent and extensive in mice lacking u-PA or Plg. Although our
results demonstrate that migration of smooth muscle cells re-
quires plasmin proteolysis, it is possible that PAI-1 may also
influence cellular migration by affecting vitronectin-dependent
cell adhesion through an interaction with the avb3-integrin recep-
tor [94]. However, vitronectin and PAI-1 poorly colocalized in the
murine healing arteries [238].
That u-PAR deficient arteries developed a similar degree of
neointima was not due to lack of u-PAR expression in wild-type
arteries, as revealed by the expression of functional u-PAR by
smooth muscle cells in vitro and in vivo [245]. Instead, immuno-
gold labeling of u-PA in injured arteries revealed that u-PA was
present on the cell surface of wild-type smooth muscle cells and
accumulated in the pericellular milieu (associated with extracel-
lular matrix components such as collagen fibers) around u-PAR
deficient cells [245]. In fact, u-PA accumulated to slightly in-
creased levels in the pericellular milieu. Degradation of 125I-
labeled fibrin after eight hours or activation of proMMP-9 and
proMMP-13 was similar in wild-type and in u-PAR deficient cells.
Taken together, these data suggest that sufficient pericellular
plasmin proteolysis is present in the absence of binding of u-PA to
its cellular receptor. Possibly, the role of u-PAR in particular
biological processes depends on its topographical and temporo-
spatial expression patterns. Somewhat surprisingly, no genotypic
differences were observed in re-endothelialization [236, 238, 245,
246], suggesting a cell-type specific requirement of plasmin pro-
teolysis for cellular migration.
More recently, the role of MMPs was investigated. Only low
levels of MMP-2 were detected in a quiescent artery. In contrast,
following injury, significantly induced expression levels of MMP-2,
MMP-3, MMP-9, MMP-12 and MMP-13 were observed across
the entire injured vessel wall [377]. Similar levels of proMMP-2
and active MMP-2 were observed in arterial extracts of wild-type
and Plg deficient mice, confirming that activation of proMMP2 is
not dependent on plasmin (see also below). In contrast, signifi-
cantly lower levels of active MMP-9 were present in Plg deficient
than in wild-type arteries. Since MMP-9 is primarily expressed by
leukocytes, and leukocytes are involved in the healing of the
injured arteries, the lower active MMP-9 levels may contribute to
the impaired medial and adventitial remodeling and to the
reduced neointima formation.
The involvement of plasmin proteolysis in neointima formation
was supported by intravenous injection in PAI-1 deficient mice of
a replication-defective adenovirus expressing human PAI-1 [238].
This resulted in preferential infection of hepatocytes and in more
than 100- to 1000-fold increased plasma PAI-1 levels. Although
the injured arterial segment was not infected, PAI-1 immunnore-
activity was detected in the developing neointima, presumably due
to deposition of plasma PAI-1. This resulted in a similar degree of
inhibition of neointima formation as observed in u-PA deficient
mice without noticeable toxic liver necrosis or intravascular
thrombosis. Proteinase-inhibitors have been suggested as anti-
restenosis drugs, and recent studies indicate that seeding of
retrovirally transduced smooth muscle cells, expressing high levels
of PAI-1, inhibits balloon angioplasty-induced arterial stenosis
(Clowes et al, personal communication). In addition, use of a viral
PAI-1-like serpin (SERP-1) reduces lesion formation in choles-
terol-fed injured rabbits [378]. Our studies suggest that strategies
aimed at reducing u-PA-mediated plasmin proteolysis may be
beneficial for reduction or prevention of restenosis. However,
antifibrinolytic strategies should be targeted at inhibiting plasmin
proteolysis and not at preventing the interaction of u-PA with its
receptor. In addition, PAI-1 gene therapy should be balanced,
since excessive inhibition of u-PA may prevent the healing of the
injured vessel wall, possibly rendering it more susceptible to
rupture.
Allograft transplant stenosis. More recently, we (in a collabora-
tion with V. Shi and E. Haber, Harvard, Boston, MA, USA) have
started to analyze the role of the plasminogen system in a mouse
model of transplant arteriosclerosis, which in many ways mimics
the accelerated arteriosclerosis in coronary arteries of trans-
planted cardiac allografts in humans [379]. In this model, host-
derived leukocytes adhere to and infiltrate beneath the endothe-
lium and form a predominantly leukocyte-rich neointima within
15 days after transplantation, whereas, at later times, smooth
muscle cells, derived from the donor graft, accumulate in the
neointima. Since previous targeting studies have shown that
migration of leukocytes and smooth muscle cells is dependent on
plasmin proteolysis [236, 238, 245, 246, 380], carotid arteries from
B.10A(2R) wild-type mice were transplanted in C57Bl6:129 Plg
deficient mice. Neointima formation within 15 days was not
significantly different, although significantly more leukocytes in-
filtrated into the media in wild-type than in Plg deficient mice. In
addition, adventitial infiltration by leukocytes and accumulation
of myofibroblasts was markedly greater in wild-type than in Plg
deficient mice. Within 45 days after transplantation, the neointima
was, however, much smaller and 10-fold fewer a-actin positive
smooth muscle cells were present in Plg deficient than in wild-type
mice. In addition, media necrosis was less pronounced, whereas
fragmentation of the elastic laminae and neoadventitia formation
were more severe in wild-type than in Plg deficient mice. Graft
thrombosis was, however, much more frequent and extensive in
Plg deficient mice. Expression of u-PA, t-PA, MMP-2, MMP-3,
MMP-9, MMP-12 and MMP-13 was significantly increased within
15 days after transplantation, when cells actively migrate. Notably,
the reverse transplantation of Plg deficient arteries into wild-type
recipients did not affect the development of the neointima,
indicating that plasminogen circulating in the plasma is essential.
In summary, it appears that plasmin is not essential for leuko-
cytes to adhere and to migrate beneath the endothelium (as also
suggested by the similar size of atherosclerotic plaques in mice
lacking t-PA or u-PA; see below). However, plasmin mediates
lysis of arterial thrombi, and is required for leukocytes to fragment
the elastic laminae and to infiltrate into the media. Similar to the
atherosclerotic aorta (see below), destruction of the medial
stroma was conditional on prior elastic lamina degradation by
macrophages. Since plasmin is unable to degrade elastin, collagen
and other matrix components in the media, it presumably acti-
vates other matrix degrading proteinases, likely of the MMP
family (see also below). Subsequently, medial smooth muscle cells
proliferate and migrate into the intima, a process that is also
mediated by plasmin.
Atherosclerosis. Atherosclerotic lesions initially consist of sub-
endothelial accumulations of foamy macrophages (fatty streaks)
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that subsequently develop into fibroproliferative lesions by infil-
tration of myofibroblasts and accumulation of extracellular matrix
[287]. A fibrous cap rich in smooth muscle cells and extracellular
matrix overlies a central necrotic core containing dying cells,
calcifications and cholesterol crystals. As long as these lesions do
not critically limit blood flow, they may grow insidiously. However,
clinical syndromes of myocardial or peripheral tissue ischemia due
to occluding thrombosis are frequently triggered by rupture of
unstable plaques, and constitute the primary cause of cardiovas-
cular morbidity and mortality in Western societies. In addition,
the atherosclerotic wall may become thinner due to media necro-
sis, ultimately resulting in aneurysm formation and fatal bleeding.
Aneurysm formation is the 13th cause of mortality, responsible for
more than 15,000 deaths annually in the United States alone [325,
381, 382]. The pathogenic mechanisms of atherosclerotic aneu-
rysm remain, however, largely undefined.
Epidemiologic, genetic and molecular evidence suggests that
impaired fibrinolysis resulting from increased PAI-1 or reduced
t-PA expression, or from inhibition of plasminogen activation,
may contribute to the development and/or progression of athero-
sclerosis [383–385]. Presumably, this results from increased
thrombosis and matrix deposition, which promote plaque growth.
Indeed, PAI-1 plasma levels are elevated in patients with ischemic
heart disease, angina pectoris and recurrent myocardial infarction
[386]. Recent genetic analyses revealed a link between polymor-
phisms in the PAI-1 promoter and the susceptibility to athero-
thrombosis [384]. Adipocytes may significantly contribute to the
increased plasma PAI-1 levels in obese patients prone to ischemic
heart disease. A possible role for increased plasmin proteolysis in
atherosclerosis is, however, suggested by the enhanced expression
of t-PA and u-PA in plaques [387, 388]. Plasmin proteolysis might
indeed participate in plaque neovascularization, induction of
plaque rupture, or in ulceration and formation of aneurysms [387,
388]. A causative role of the plasminogen system in these pro-
cesses has, however, not been conclusively demonstrated.
Therefore, atherosclerosis was studied in mice deficient in
apolipoprotein E (apoE) [389], or deficient in apoE and t-PA,
u-PA or PAI-1, and fed a cholesterol-rich diet for 5 to 25 weeks
[230]. No differences in the size or the predilection site of early
fatty streaks and more advanced plaques were observed between
mice with a deficiency of apoE or with a combined deficiency of
apoE and t-PA, or of apoE and u-PA, suggesting that plasmin is
not essential for subendothelial infiltration by macrophages. Ap-
parently, deficiency in apoE and Plg results in accelerated athero-
sclerosis [390]. Whether this is due to a direct effect of plasmin-
ogen deficiency on matrix deposition (fibrin deposition did,
however, not appear to be different), or cellular function within
the plaque, or instead results from an indirect systemic effect, was
not elucidated. Indeed, the poor general health of the Plg
deficient mice with their associated generalized state of increased
inflammatory stress, as well as their significantly lower levels of
high density lipoproteins, may have contributed to the accelerated
atherosclerosis [390].
In contrast, mice with a combined deficiency of apoE and PAI-1
developed normal fatty streak lesions, but subsequently revealed a
transient delayed progression to fibroproliferative plaques (un-
published observations). Whether the increased plasmin proteo-
lytic balance in these mice might prevent matrix accumulation
and, consequently, delay plaque progression, or whether more
abundant plasmin increased activation of latent TGF-b1 with its
pleiotropic role on smooth muscle cell function and matrix
accumulation, remains to be determined. Taken together, these
targeting studies identify a specific role for u-PA in the destruc-
tion of the media that may precede aneurysm formation, and for
PAI-1 in plaque progression, possibly by promoting matrix depo-
sition.
Significant genotypic differences were observed in the integrity
of the atherosclerotic aortic wall [230]. Indeed, destruction of the
media with resultant erosion, transmedial ulceration, necrosis of
medial smooth muscle cells, aneurysmal dilation and rupture of
the vessel wall were more prevalent and severe in mice lacking
apoE or apoE:t-PA than mice lacking apoE:u-PA. At the ultra-
structural level, elastin fibers were eroded, fragmented and com-
pletely degraded, and collagen bundles and glycoprotein-rich
matrix were disorganized and scattered in apoE deficient and
apoE:t-PA deficient mice, whereas apoE:u-PA deficient mice
were virtually completely protected. Mac3 immunostaining and
ultrastructural analysis revealed that macrophages were absent in
the media of uninvolved arteries, that they were only able to
infiltrate into the media of atherosclerotic arteries after they
degraded the elastin fibers, and that media destruction progressed
in an intima-to-adventitial gradient. Plaque macrophages (and
especially those infiltrating into the media) expressed abundant
amounts of u-PA mRNA, antigen and activity at the base of the
plaque, similar to those in patients [387, 388]. In contrast, t-PA
and PAI-1 were confined to the more apical regions within the
plaque. Thus, a dramatic increase of free u-PA activity (which is
minimal in quiescent arteries) was generated by the infiltrating
plaque macrophages. Since plasmin by itself is unable to degrade
insoluble elastin or fibrillar collagen, it most likely activated other
matrix proteinases. Because of their well-described increased
expression in atherosclerotic plaques and aneurysms, matrix met-
alloproteinases (MMPs) constituted likely candidates. Macro-
phages in murine atherosclerotic plaques abundantly expressed
MMP-3, MMP-9, MMP-12 and MMP-13 [230]. Furthermore,
cultured peritoneal macrophages derived from wild-type mice, or
mice deficient in t-PA, MMP-3, MMP-7 and MMP-9 degraded
3H-elastin in a plasminogen-dependent manner, whereas u-PA
deficient or MMP-12 deficient macrophages were unable to do so.
In addition, wild-type and t-PA deficient but not u-PA deficient
cultured macrophages activated secreted proMMP-3, proMMP-9,
proMMP-12 and proMMP-13, but only in the presence of plas-
minogen, indicating that u-PA-generated plasmin was responsible
for activation of these proMMPs. These plasmin-activatable met-
alloproteinases colocalized with u-PA in plaque macrophages.
Another possible mechanism of action of plasmin is that it
mediates the degradation of glycoproteins in the stroma of the
aortic wall, thereby exposing the highly insoluble elastin to
elastases and facilitating elastolysis in vivo [391]. Our unpublished
data that u-PA deficient macrophages degraded 3H-fucose la-
beled glycoproteins in a subendothelial matrix less efficiently than
wild-type macrophages support such a role. Taken together, these
results suggest an important role of u-PA in the structural
integrity of the atherosclerotic vessel wall, likely via triggering
activation of matrix metalloproteinases. Direct proof of whether
and which MMPs are involved in media destruction and aneurysm
formation has to await a similar analysis in mice that are deficient
of apoE and each of these MMPs combined.
Myocardial ischemia. Acute myocardial infarction due to the
occlusion of coronary arteries is a leading cause of morbidity and
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mortality in Western societies. Despite the therapeutic benefits of
trombolysis, coronary angioplasty and bypass surgery, myocardial
performance is severely disabled and the associated arrhythmias
and ventricular wall rupture represent a significant cause of
sudden death [281, 392]. In addition, chronic heart failure fre-
quently results from infarct expansion, mitral valve insufficiency
and left ventricular aneurysm formation. Therefore, a better
understanding of the pathophysiological mechanisms leading to
ventricular wall rupture and myocardial scar formation is man-
dated.
Sudden death due to ventricular wall rupture or infarct expan-
sion usually occurs within five days after myocardial infarction in
human patients, coincident with the invasion of inflammatory cells
and endothelial cells, and the diffuse myocytolysis. Infarct expan-
sion (characterized by a disproportional regional thinning and
dilation of the ventricular wall due to stretching and slippage of
myocytes in the ischemic area) is a frequent complication of
transmural infarcts and is associated with heart failure, cardiac
rupture and increased mortality. Excessive degradation of fibrillar
collagen I and III (the most abundant cardiac interstitial matrix
components) by infiltrating leukocytes and endothelial cells
(which produce significant amounts of PAs and MMPs) may cause
infarct expansion and heart rupture.
Within one to two weeks after myocardial ischemia, a highly
vascularized granulation tissue rich in infiltrating fibroblasts re-
moves the cellular debris and mediates collagen deposition, which
ultimately leads to the scar formation [59]. Aneurysms cause
expansive ventricular paradoxical wall motion and may become
progressively complicated by congestive heart failure, arterial
embolism, and arrhythmias. Myofibroblasts mediate this process
since they produce increased levels of TIMP within one week after
ischemia, and produce abundant amounts of collagen I and III.
Fibronectin and laminin may bridge the myocyte cell surface with
the collagen fibers in the pericellular matrix and may be involved
in cell adhesion, migration and proliferation during cardiac wound
healing. Apart from their role in cardiac remodeling, proteinases
may also be involved in collateral growth of the ischemic myocar-
dium (see above). Currently, however, little is known about the
role of the PA and MMP proteinases, and their interaction, in
myocardial infarction and scar formation.
Recently, a modified mouse model of chronic myocardial
infarction has been used to evaluate the role of the plasminogen
system in cardiac healing (Daemen et al, personal communica-
tion). Initial studies reveal that the plasminogen system is impor-
tantly involved in this process (observation in collaboration with
M. Daemen and J. Smits, Maastricht, the Netherlands). Indeed,
following ligation of the left anterior descending coronary artery,
wild-type or t-PA deficient mice heal their ischemic myocardium
within two weeks via scar formation; that is, the ishemic myocar-
dium becomes infiltrated by leukocytes, endothelial cells and
fibroblasts with resultant deposition of collagen. In a fraction of
these mice, rupture of the ischemic myocardium occurs shortly
after infarction, possibly related to excessive u-PA-generated
plasmin proteolysis by infiltrating wound cells. In sharp contrast,
mice lacking u-PA or Plg are protected against ventricular wall
rupture, but fail to heal the ischemic myocardium, which remains
largely devoid of infiltrating leukocytes, endothelial cells and
fibroblasts. Mural thrombosis in the ventricular cavity occurred
more frequently, however, in Plg and u-PA deficient mice than in
wild-type mice. How these morphologic observations correlate
with expression of fibrinolytic or matrix metalloproteinase en-
zymes and whether cardiac function is affected differently in the
various genotypes remains to be determined. Nevertheless, the
data show that u-PA-generated plasmin proteolysis is required for
healing, but needs to be carefully balanced to avoid tissue
destruction and ventricular wall rupture. Studies are underway to
investigate the role of the various MMPs in the respective
knockout mice.
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APPENDIX
Abbreviations used in this article are: aFGF, acidic fibroblast
growth factors (also FGF1); ANG, angiopoietins; ARNT, arylhy-
drocarbon-receptor nuclear translocator; bFGF, basic fibroblast
growth factor (also FGF2); FGF, fibroblast growth factors; FLK1,
VEGF receptor-2; FLT1, VEGF receptor-1; HIF, hypoxia-induc-
ible factor; IGF, insulin-like growth factor; MMPs, matrix metal-
loproteinases; PAs, plasminogen activators; PAI-1, plasminogen
activator inhibitor-1; PDGF, platelet-derived growth factor; PlGF,
placental growth factor; TF, tissue factor; TFPI, tissue factor
pathway inhibitor; TGF-B, transforming growth factor-B; TIE1,
tyrosine kinase with immunoglobulin and epidermal growth factor
homology domains; TIE2/TEK, tunica interna endothelial cell
kinase; TIMPs, tissue inhibitor of matrix metalloproteinases;
TNF-a, tubular necrosis factor-a; t-PA, tissue-type PA; u-PA,
urokinase-type plasminogen activator; u-PAR, urokinase plasmin-
ogen activator receptor; VE, vascular endothelial; VEGF, vascu-
lar endothelial growth factor; VEGFR, vascular endothelial
growth factor receptor.
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